



(86) Date de dépôt PCT/PCT Filing Date: 2010/05/20
(87) Date publication PCT/PCT Publication Date: 2010/11/25
(85) Entrée phase nationale/National Entry: 2011/11/07
(86) N° demande PCT/PCT Application No.: US 2010/035573
(87) N° publication PCT/PCT Publication No.: 2010/135530
(30) Priorité/Priority: 2009/05/20 (US61/180,102)

(51) Cl.Int./Int.Cl. *C07D 333/10* (2006.01)
(71) Demandeur/Applicant:
ARDEA BIOSCIENCES, INC., US
(72) Inventeurs/Inventors:
DE LA ROSA, MARTHA, US;
GIRARDET, JEAN-LUC, US
(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSES, COMPOSITIONS ET PROCEDES POUR MODULER DES TAUX D'ACIDE URIQUE
(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS

(57) **Abrégé/Abstract:**

Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 November 2010 (25.11.2010)



(10) International Publication Number
WO 2010/135530 A3

(51) International Patent Classification:
C07D 333/10 (2006.01)

(21) International Application Number:
PCT/US2010/035573

(22) International Filing Date:
20 May 2010 (20.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/180,102 20 May 2009 (20.05.2009) US

(71) Applicant (for all designated States except US): **ARDEA BIOSCIENCES, INC.** [US/US]; 4939 Directors Place, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE LA ROSA, Martha** [US/US]; 1026 Country Lane, Durham, North Carolina 27713 (US). **GIRARDET, Jean-Luc** [FR/US]; 16763 Santa Corina Court, San Diego, California 92127 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
19 May 2011

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS

(57) Abstract: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.



WO 2010/135530 A3

COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS

CROSS-REFERENCE


- 5 [0001] This application claims the benefit of U.S. Provisional Application No. 61/180,102, filed May 20, 2009, which application is incorporated herein by reference.

BACKGROUND OF THE INVENTION

- 10 [0002] Aberrant uric acid levels are related to several disorders including, but not limited to, gout, gouty arthritis, inflammatory arthritis, kidney disease, nephrolithiasis (kidney stones), joint inflammation, deposition of urate crystals in joints, urolithiasis (formation of calculus in the urinary tract), deposition of urate crystals in renal parenchyma, Lesch-Nyhan syndrome, and Kelley-Seegmiller syndrome.


15 SUMMARY OF THE INVENTION

- [0003] Disclosed herein, in certain embodiments, are compounds of Formula (I):



wherein:

- 20 R^1 is an electron lone pair, H, Br, Cl, Br, I, NH_2 , methyl, ethyl, *n*-propyl, *i*-propyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted *n*-propyl, optionally substituted *i*-propyl, CF_3 , CHF_2 or CH_2F ;



- 25 wherein each R^{4a} and R^{4b} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; or R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N; each R^{4c} and R^{4d} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 ,


NHCH₃; R^P is H, methyl, ethyl, propyl, *i*-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or CN;

R³ is -X-CR^{5a}R^{5b} - (CR^{6a}R^{6b})_n-C(O)-O-R^M wherein X is S or O; each R^{5a}, R^{5b}, R^{6a} and R^{6b} is independently selected from H, F, Cl, Br, CH₃ and CF₃; n is 0 or 1; and R^M is H, a pharmaceutically acceptable cation, substituted or unsubstituted (C₁₋₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a prodrug moiety;


Ar is a 5-membered aromatic heterocycle comprising from one to four heteroatoms each independently selected from O, N and S; and

wherein the groups R¹, R² and R³ are immediately adjacent to each other.


[0004] In some embodiments, Ar is a pyrrole, a pyrazole, an imidazole, a triazole, a tetrazole, an oxazole, a thiazole, an isoxazole, an isothiazole, an oxadiazole or a thiadiazole. In some embodiments, Ar is a pyrrole of Formula (II-A), (II-B), (II-C) or (II-D):




(II-A)



(II-B)




(II-C)




(II-D)


or a tautomer thereof. In some embodiments, R¹ is H and Ar is a pyrrole of Formula (III-A), (III-B), (III-C) or (III-D):




(III-A)



(III-B)




(III-C)




(III-D)


or a tautomer thereof. In some embodiments, Ar is a pyrazole or an imidazole of Formula (IV-A), (IV-B), (IV-C), (IV-D) or (IV-E):




(IV-A)




(IV-B)



(IV-C)




(IV-D)




(IV-E)

or a tautomer thereof. In some embodiments, Ar is a triazole of Formula (V-A) or (V-B):




(V-A)




(V-B)

or a tautomer thereof. In some embodiments, R¹ is H and Ar is a tetrazole of Formula (VI):




(VI)


or a tautomer thereof. In some embodiments, Ar is an oxazole, a thiazole, an isoxazole or an isothiazole of Formula (VII-A), (VII-B), (VII-C) or (VII-D):




(VII A)



(VII B)




(VII C)




(VII D)


or a tautomer thereof. In some embodiments, R¹ is H and Ar is an oxazole, a thiazole, an isoxazole or an isothiazole of Formula (VIII-A), (VIII-B), (VIII-C), (VIII-D), (VIII-E), (VIII-F), (VIII-G), (VIII-H), (VIII-I), (VIII-J), (VIII-K) or (VIII-L):




(VIII-A)




(VIII-B)




(VIII-C)




(VIII -D)




(VIII-E)




(VIII-F)




(VIII-G)




(VIII-H)




(VIII-I)



(VIII-J)




(VIII-K)




(VIII-L)


or a tautomer thereof. In some embodiments, R¹ is H and Ar is an oxadiazole or a thiadiazole of Formula (IX-A), (IX-B), (IX-C), (IX-D), (IX-E) or (IX-F):




(IX-A)




(IX-B)




(IX-C)



(IX-D)




(IX-E)




(IX-F)

or a tautomer thereof. In some embodiments, R¹ is an electron lone pair. In some embodiments, R¹ is



H. In some embodiments, R¹ is Br. In some embodiments, R² is: R^P. In some embodiments, R^{4a}

and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each




independently selected from O, S and N. In some embodiments, R^2 is R^P . In some embodiments, R^P is cyclopropyl or CN. In some embodiments, X is O. In some embodiments, X is S.

5 In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, R^{5a} is H and R^{5b} is H. In some embodiments, R^{5a} is F and R^{5b} is F. In some embodiments, n is 0, R^{5a} is H and R^{5b} is H. In some embodiments, n is 0, R^{5a} is F and R^{5b} is F.

In some embodiments, R^M is H. In some embodiments, R^M is a pharmaceutically acceptable cation.

In some embodiments, n is 0, R^{5a} is F and R^{5b} is F.


10 **[0005]** Disclosed herein, in certain embodiments, is a method of inhibiting a URAT-1 transporter,



comprising contacting the URAT-1 transporter with a compound of Formula (I):

wherein:

R^1 is an electron lone pair, H, Br, Cl, Br, I, NH_2 , methyl, ethyl, *n*-propyl, *i*-propyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted *n*-propyl, optionally substituted *i*-propyl, CF_3 , CHF_2 or CH_2F ;



R^2 is R^P wherein each R^{4a} and R^{4b} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; or R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N; each R^{4c} and R^{4d} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; R^P is methyl, ethyl, propyl, *i*-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or CN;

25 R^3 is $-X-CR^{5a}R^{5b}-(CR^{6a}R^{6b})_n-C(O)-O-R^M$ wherein X is S or O; each R^{5a} , R^{5b} , R^{6a} and R^{6b} is independently selected from H, F, Cl, Br, CH_3 and CF_3 ; n is 0 or 1; and R^M is H, a

pharmaceutically acceptable cation, substituted or unsubstituted (C₁₋₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a prodrug moiety;

Ar is a 5-membered aromatic heterocycle comprising from one to four heteroatoms each independently selected from O, N and S; and

wherein the groups R¹, R² and R³ are immediately adjacent to each other.

[0006] Disclosed herein, in certain embodiments, is a method for decreasing uric acid levels in one or more tissues or organs of a subject in need of decreased uric acid levels, comprising administering to the subject a uric acid level decreasing amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

In some embodiments, the subject in need of decreased uric acid levels has a disorder characterized by an abnormally high content of uric acid in one or more tissues or organs of the subject. In some embodiments, the disorder is characterized by overproduction of uric acid, low excretion of uric acid, tumor lysis, a blood disorder or a combination thereof. In some embodiments, the blood disorder is polycythemia or myeloid metaplasia. In some embodiments, the subject in need of decreased uric acid levels is suffering from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis. In some embodiments, tissue or organ is blood. In some embodiments, the blood uric acid level is decreased by at least about 1mg/dL. In some embodiments, the blood uric acid level is decreased by at least about 2mg/dL. In some embodiments, the uric acid levels are decreased by at least about 10% in one or more tissues or organs of the subject. In some embodiments, the uric acid levels are decreased by at least about 25% in one or more tissues or organs of the subject. In some embodiments, the uric acid levels are decreased by at least about 50% in one or more tissues or organs of the subject.

[0007] Disclosed herein, in certain embodiments, is a method for decreasing uric acid levels in one or more tissues or organs of a subject comprising administering to the subject a uric acid level decreasing amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, wherein the reduction in uric acid levels results in a reduction in hypertension or cardiovascular events.

[0008] Disclosed herein, in certain embodiments, is a method for reducing uric acid production, increasing uric acid excretion or both in a subject, comprising administering to the subject a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[0009] Disclosed herein, in certain embodiments, is a method for treating or preventing hyperuricemia in a subject comprising administering to the subject an effective amount of a

compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[0010] Disclosed herein, in certain embodiments, is a method of treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid comprising administering to the subject an effective amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. In some embodiments, the condition is characterized by low tissue levels of uric acid. In some embodiments, the condition is characterized by high tissue levels of uric acid. In some embodiments, the condition is selected from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis. In some embodiments, the condition is gout. In some embodiments, the condition is joint inflammation. In some embodiments, the joint inflammation is caused by deposits of uric acid crystals in the joint. In some embodiments, the uric acid crystals are deposited in the joint fluid (synovial fluid) or joint lining (synovial lining). In some embodiments, the method further comprises administering an agent effective for the treatment of the condition. In some embodiments, the agent is effective in reducing tissue levels of uric acid. In some embodiments, the agent is a nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, a corticosteroid, adrenocorticotrophic hormone (ACTH), probenecid, sulfinpyrazone or allopurinol. In some embodiments, the agent is allopurinol.

[0011] Disclosed herein, in certain embodiments, is a method for preventing a condition characterized by abnormal tissue levels of uric acid in a subject at increased risk of developing the condition, comprising administering to the subject an effective amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. In some embodiments, the condition is selected from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis.

[0012] Disclosed herein, in certain embodiments, is a method for treating gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis in a subject comprising administering to the subject an effective amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[0013] Disclosed herein, in certain embodiments, is a method for treating gout in a subject comprising administering to the subject an effective amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. In some embodiments, the method further comprises administering an agent effective for the treatment of the gout. In some embodiments, the agent is allopurinol.

[0014] Disclosed herein, in certain embodiments, is a method for preventing the formation or reducing the size of tophi/tophus in a subject, comprising administering to the subject an effective amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[0015] Disclosed herein, in certain embodiments, is a method for treating hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency in a subject comprising administering to the subject a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[0016] Disclosed herein, in certain embodiments, is a pharmaceutical composition comprising: a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof; ii) allopurinol; and iii) optionally one or more pharmaceutically acceptable carriers.

[0017] Disclosed herein, in certain embodiments, is a pharmaceutical composition comprising: a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof; ii) at least one agent selected from the group consisting of a nonsteroidal anti-inflammatory drug (NSAID), Ibuprofen, Naproxen, Colchicine, Probenecid and Sulfapyrazone; and iii) optionally one or more pharmaceutically acceptable carriers.

[0018] Disclosed herein, in certain embodiments, is a pharmaceutical composition useful in the treatment of edema and hypertension which also maintains uric acid levels at pretreatment levels or causes a decrease in uric acid levels comprising: at least one antihypertensive agent; ii) a uric acid level maintaining or lowering amount of a compound of the Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof; and iii) optionally one or more pharmaceutically acceptable carriers.

[0019] Disclosed herein, in certain embodiments, is a pharmaceutical composition useful in the treatment of cancer which also maintains uric acid levels at pretreatment levels or causes a decrease in uric acid levels comprising: at least one anticancer agent; ii) a uric acid level maintaining or lowering amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof; and iii) optionally one or more pharmaceutically acceptable carriers.

[0020] Disclosed herein, in certain embodiments, is a pharmaceutical composition useful for reducing the side effects of chemotherapy in a cancer patient, comprising: a uric acid level

maintaining or lowering amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof; and ii) optionally one or more pharmaceutically acceptable carriers.

5

DETAILED DESCRIPTION

Methods: Aberrant uric Acid Levels

[0021] The present invention also provides methods useful for diseases or disorders related to aberrant uric acid levels. The method includes administering an effective amount of a composition as described herein to a subject with aberrant levels of uric acid such as to restore acceptable or non-aberrant levels of uric acid. The present invention also provides methods useful for decreasing uric acid levels in one or more tissues or organs of a subject in need of decreased uric acid levels, comprising administering to the subject a uric acid level decreasing amount of a composition as described herein. The present invention also provides methods useful for reducing uric acid production, increasing uric acid excretion or both in a subject, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating or preventing hyperuricemia in a subject comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating a subject suffering from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for preventing a condition characterized by abnormal tissue levels of uric acid in a subject at increased risk of developing the condition, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis in a subject comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating gout in a subject comprising administering to the subject an effective amount of a composition as described herein. The present

invention also provides methods useful for preventing the formation or reducing the size of tophi/tophus in a subject, comprising administering to the subject an effective amount of a composition as described herein.

5 ***Certain Chemical Terminology***

[0022] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. In the event that there is a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that
10 such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet or other appropriate reference source. Reference thereto evidences the availability and public dissemination of such information.

[0023] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed.

15 In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. It should also be noted that use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes”, and “included” is not limiting.

20 [0024] Definition of standard chemistry terms are found in reference works, including Carey and Sundberg “ADVANCED ORGANIC CHEMISTRY 4TH ED.” Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, IR and UV/Vis spectroscopy and pharmacology, are employed.

25 [0025] Where substituent groups are specified by their conventional chemical formulas, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left. As a non-limiting example, -CH₂O- is equivalent to -OCH₂-.

[0026] Unless otherwise noted, the use of general chemical terms, such as though not limited to “alkyl,” “amine,” “aryl,” are equivalent to their optionally substituted forms. For example, “alkyl,”
30 as used herein, includes optionally substituted alkyl.

[0027] In some embodiments, the compounds presented herein possess one or more stereocenters. In some embodiments, each center exists in the R or S configuration, or combinations thereof. In some embodiments, the compounds presented herein possess one or more double bonds. In some embodiments, each double bond exists in the E (*trans*) or Z (*cis*) configuration, or combinations
35 thereof. Presentation of one particular stereoisomer, regioisomer, diastereomer, enantiomer or epimer should be understood to include all possible stereoisomers, regioisomers, diastereomers,

enantiomers or epimers and mixtures thereof. Thus, the compounds presented herein include all separate configurational stereoisomeric, regioisomeric, diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are found, for example, Furniss *et al.* (eds.), VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5. sup. TH ED., Longman Scientific and Technical Ltd., Essex, 1991, 809-816; and Heller, *Acc. Chem. Res.* 1990, 23, 128.

[0028] The terms “moiety”, “chemical moiety”, “group” and “chemical group”, as used herein refer to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.

[0029] The term “reactant,” as used herein, refers to a nucleophile or electrophile used to create covalent linkages.

[0030] The term “bond” or “single bond” refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.

[0031] The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl”. Further, an optionally substituted group means unsubstituted (e.g., -CH₂CH₃), fully substituted (e.g., -CF₂CF₃), mono-substituted (e.g., -CH₂CH₂F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH₂CHF₂, -CH₂CF₃, -CF₂CH₃, -CFHCHF₂, etc). With respect to any group containing one or more substituents, such groups are not intended to introduce any substitution or substitution patterns (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially *ad infinitum*) that are sterically impractical and/or synthetically non-feasible. Thus, any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons (except in those instances where macromolecular substituents are clearly intended, e.g., polypeptides, polysaccharides, polyethylene glycols, DNA, RNA and the like).

[0032] As used herein, C₁-C_x includes C₁-C₂, C₁-C₃ . . . C₁-C_x. By way of example only, a group designated as “C₁-C₄” indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms, as well as the ranges C₁-C₂ and C₁-C₃. Thus, by way of example only, “C₁-C₄ alkyl” indicates that there are one to four carbon atoms in the alkyl group, *i.e.*, the alkyl group is selected from among methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl, and *t*-butyl. Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; *e.g.*, “1 to 10 carbon atoms” means 1

carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.

[0033] The term “lower” as used herein in combination with terms such as alkyl, alkenyl or alkynyl, (i.e. “lower alkyl”, “lower alkenyl” or “lower alkynyl”) refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about six carbon atoms, more preferably one to three carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl.

[0034] The term “hydrocarbon” as used herein, alone or in combination, refers to a compound or chemical group containing only carbon and hydrogen atoms.

[0035] The terms “heteroatom” or “hetero” as used herein, alone or in combination, refer to an atom other than carbon or hydrogen. Heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin, but are not limited to these atoms. Where two or more heteroatoms are present, in some embodiments, the two or more heteroatoms are the same as each another. Where two or more heteroatoms are present, in some embodiments, the two or more heteroatoms are different from the others.

[0036] The term “alkyl” as used herein, alone or in combination, refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl and the like. Whenever it appears herein, a numerical range such as “C₁-C₆ alkyl” or “C₁₋₆ alkyl”, means that: in some embodiments, the alkyl group consists of 1 carbon atom; in some embodiments, 2 carbon atoms; in some embodiments, 3 carbon atoms; in some embodiments, 4 carbon atoms; in some embodiments, 5 carbon atoms; in some embodiments, 6 carbon atoms. The present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.

[0037] The term “alkylene” as used herein, alone or in combination, refers to a diradical derived from the above-defined monoradical, alkyl. Examples include, but are not limited to methylene (-CH₂-), ethylene (-CH₂CH₂-), propylene (-CH₂CH₂CH₂-), isopropylene (-CH(CH₃)CH₂-) and the like.

[0038] The term “alkenyl” as used herein, alone or in combination, refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group includes either the *cis* or *trans* conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl ($-\text{CH}=\text{CH}_2$), 1-propenyl ($-\text{CH}_2\text{CH}=\text{CH}_2$), isopropenyl [$-\text{C}(\text{CH}_3)=\text{CH}_2$], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C₂-C₆ alkenyl” or “C₂₋₆ alkenyl”, means that: in some embodiments, the alkenyl group consists of 2 carbon atoms; in some embodiments, 3 carbon atoms; in some embodiments, 4 carbon atoms; in some
 10 embodiments, 5 carbon atoms; in some embodiments, 6 carbon atoms. The present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.

[0039] The term “alkenylene” as used herein, alone or in combination, refers to a diradical derived from the above-defined monoradical alkenyl. Examples include, but are not limited to ethenylene ($-\text{CH}=\text{CH}-$), the propenylene isomers (e.g., $-\text{CH}_2\text{CH}=\text{CH}-$ and $-\text{C}(\text{CH}_3)=\text{CH}-$) and the like.

[0040] The term “alkynyl” as used herein, alone or in combination, refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butyne, 1,3-butadiynyl and the like. Whenever it appears herein, a numerical range such as “C₂-C₆ alkynyl” or “C₂₋₆ alkynyl”, means: in some embodiments, the alkynyl group consists of 2 carbon atoms; in some embodiments, 3 carbon atoms; in some embodiments, 4 carbon atoms; in some embodiments, 5 carbon atoms; in some embodiments, 6 carbon atoms. The present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated.

[0041] The term “alkynylene” as used herein, alone or in combination, refers to a diradical derived from the above-defined monoradical, alkynyl. Examples include, but are not limited to ethynylene ($-\text{C}\equiv\text{C}-$), propargylene ($-\text{CH}_2-\text{C}\equiv\text{C}-$) and the like.

[0042] The term “aliphatic” as used herein, alone or in combination, refers to an optionally substituted, straight-chain or branched-chain, non-cyclic, saturated, partially unsaturated, or fully unsaturated nonaromatic hydrocarbon. Thus, the term collectively includes alkyl, alkenyl and
 30 alkynyl groups.

[0043] The terms “heteroalkyl”, “heteroalkenyl” and “heteroalkynyl” as used herein, alone or in combination, refer to optionally substituted alkyl, alkenyl and alkynyl structures respectively, as described above, in which one or more of the skeletal chain carbon atoms (and any associated hydrogen atoms, as appropriate) are each independently replaced with a heteroatom (i.e. an atom other than carbon, such as though not limited to oxygen, nitrogen, sulfur, silicon, phosphorous, tin or combinations thereof), or heteroatomic group such as though not limited to $-\text{O}-\text{O}-$, $-\text{S}-\text{S}-$, $-\text{O}-\text{S}-$, $-\text{S}-$

O-, =N-N=, -N=N-, -N=N-NH-, -P(O)₂-, -O-P(O)₂-, -P(O)₂-O-, -S(O)-, -S(O)₂-, -SnH₂- and the like.

[0044] The terms “haloalkyl”, “haloalkenyl” and “haloalkynyl” as used herein, alone or in combination, refer to optionally substituted alkyl, alkenyl and alkynyl groups respectively, as defined above, in which one or more hydrogen atoms is replaced by fluorine, chlorine, bromine or iodine atoms, or combinations thereof. In some embodiments, two or more hydrogen atoms are replaced with halogen atoms that are the same as each another (e.g. difluoromethyl); in other embodiments, two or more hydrogen atoms are replaced with halogen atoms that are not all the same as each other (e.g. 1-chloro-1-fluoro-1-iodoethyl). Non-limiting examples of haloalkyl groups are fluoromethyl and bromoethyl. A non-limiting example of a haloalkenyl group is bromoethenyl. A non-limiting example of a haloalkynyl group is chloroethynyl.


[0045] The term “perhalo” as used herein, alone or in combination, refers to groups in which all of the hydrogen atoms are replaced by fluorines, chlorines, bromines, iodines, or combinations thereof. Thus, as a non-limiting example, the term “perhaloalkyl” refers to an alkyl group, as defined herein, in which all of the H atoms have been replaced by fluorines, chlorines, bromines or iodines, or combinations thereof. A non-limiting example of a perhaloalkyl group is bromo, chloro, fluoromethyl. A non-limiting example of a perhaloalkenyl group is trichloroethenyl. A non-limiting example of a perhaloalkynyl group is tribromopropynyl.

[0046] The term “carbon chain” as used herein, alone or in combination, refers to any alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl or heteroalkynyl group, which is linear, cyclic, or any combination thereof. If the chain is part of a linker and that linker comprises one or more rings as part of the core backbone, for purposes of calculating chain length, the “chain” only includes those carbon atoms that compose the bottom or top of a given ring and not both, and where the top and bottom of the ring(s) are not equivalent in length, the shorter distance shall be used in determining the chain length. If the chain contains heteroatoms as part of the backbone, those atoms are not calculated as part of the carbon chain length.

[0047] The terms “cycle”, “cyclic”, “ring” and “membered ring” as used herein, alone or in combination, refer to any covalently closed structure, including alicyclic, heterocyclic, aromatic, heteroaromatic and polycyclic fused or non-fused ring systems as described herein. In some embodiments, rings are optionally substituted. In some embodiments, rings form part of a fused ring system. The term “membered” is meant to denote the number of skeletal atoms that constitute the ring. Thus, by way of example only, cyclohexane, pyridine, pyran and pyrimidine are six-membered rings and cyclopentane, pyrrole, tetrahydrofuran and thiophene are five-membered rings.


[0048] The term “fused” as used herein, alone or in combination, refers to cyclic structures in which two or more rings share one or more bonds.

[0049] The term “cycloalkyl” as used herein, alone or in combination, refers to an optionally substituted, saturated, hydrocarbon monoradical ring, containing from three to about fifteen ring carbon atoms or from three to about ten ring carbon atoms. In some embodiments, the compound includes additional, non-ring carbon atoms as substituents (e.g. methylcyclopropyl). Whenever it appears herein, a numerical range such as “C₃-C₆ cycloalkyl” or “C₃₋₆ cycloalkyl”, means: in some embodiments, the cycloalkyl group consists of 3 carbon atoms (e.g., cyclopropyl); in some embodiments, 4 carbon atoms (e.g., cyclobutyl); in some embodiments, 5 carbon atoms (e.g., cyclopentyl); in some embodiments, 6 carbon atoms (e.g., cyclohexyl). The present definition also covers the occurrence of the term “cycloalkyl” where no numerical range is designated. Further, the term includes fused, non-fused, bridged and spiro radicals. A fused cycloalkyl contains from two to four fused rings where the ring of attachment is a cycloalkyl ring, and the other individual rings are alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Examples include, but are not limited to cyclopropyl, cyclopentyl, cyclohexyl, decalyl, and bicyclo [2.2.1] heptyl and adamantyl ring systems. Illustrative examples include, but are not limited to the following moieties:



and the like.

[0050] The term “cycloalkenyl” as used herein, alone or in combination, refers to an optionally substituted hydrocarbon non-aromatic, monoradical ring, having one or more carbon-carbon double bonds and from three to about twenty ring carbon atoms, three to about twelve ring carbon atoms, or from three to about ten ring carbon atoms. The term includes fused, non-fused, bridged and spiro radicals. A fused cycloalkenyl contains from two to four fused rings where the ring of attachment is a cycloalkenyl ring, and the other individual rings are alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. In some embodiments, fused ring systems are fused across a bond that is a carbon-carbon single bond or a carbon-carbon double bond. Examples of cycloalkenyls include, but are not limited to cyclohexenyl, cyclopentadienyl and bicyclo[2.2.1]hept-2-ene ring systems. Illustrative examples include, but are not limited to the following moieties:




and the like.

[0051] The terms “alicyclic” or “alicyclic” as used herein, alone or in combination, refer to an optionally substituted, saturated, partially unsaturated, or fully unsaturated nonaromatic hydrocarbon ring systems containing from three to about twenty ring carbon atoms, three to about twelve ring

carbon atoms, or from three to about ten ring carbon atoms. Thus, the terms collectively include cycloalkyl and cycloalkenyl groups.

[0052] The terms “non-aromatic heterocyclyl” and “heteroalicyclyl” as used herein, alone or in combination, refer to optionally substituted, saturated, partially unsaturated, or fully unsaturated nonaromatic ring monoradicals containing from three to about twenty ring atoms, where one or more of the ring atoms are an atom other than carbon, independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms. Where two or more heteroatoms are present in the ring, in some embodiments, the two or more heteroatoms are the same as each another; in some embodiments, some or all of the two or more heteroatoms are different from the others. The terms include fused, non-fused, bridged and spiro radicals. A fused non-aromatic heterocyclic radical contains from two to four fused rings where the attaching ring is a non-aromatic heterocycle, and the other individual rings are alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Fused ring systems are fused across a single bond or a double bond, as well as across bonds that are carbon-carbon, carbon-hetero atom or hetero atom-hetero atom. The terms also include radicals having from three to about twelve skeletal ring atoms, as well as those having from three to about ten skeletal ring atoms. In some embodiments, attachment of a non-aromatic heterocyclic subunit to its parent molecule is via a heteroatom; in some embodiments, via a carbon atom. In some embodiments, additional substitution is via a heteroatom or a carbon atom. As a non-limiting example, an imidazolidine non-aromatic heterocycle is attached to a parent molecule via either of its N atoms (imidazolidin-1-yl or imidazolidin-3-yl) or any of its carbon atoms (imidazolidin-2-yl, imidazolidin-4-yl or imidazolidin-5-yl). In certain embodiments, non-aromatic heterocycles contain one or more carbonyl or thiocarbonyl groups such as, for example, oxo- and thio-containing groups. Examples include, but are not limited to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:



The terms also include all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.

[0053] The term “aromatic” as used herein, refers to a planar, cyclic or polycyclic, ring moiety

5 having a delocalized π -electron system containing $4n+2$ π electrons, where n is an integer. In some embodiments, aromatic rings are formed by five atoms; in some embodiments, six atoms; in some embodiments, seven atoms; in some embodiments, eight atoms; in some embodiments, nine atoms; in some embodiments, more than nine atoms. Aromatics are optionally substituted and are monocyclic or fused-ring polycyclic. The term aromatic encompasses both all carbon containing

10 rings (*e.g.*, phenyl) and those rings containing one or more heteroatoms (*e.g.*, pyridine).

[0054] The term “aryl” as used herein, alone or in combination, refers to an optionally substituted aromatic hydrocarbon radical of six to about twenty ring carbon atoms, and includes fused and non-fused aryl rings. A fused aryl ring radical contains from two to four fused rings, where the ring of attachment is an aryl ring, and the other individual rings are alicyclic, heterocyclic, aromatic,


15 heteroaromatic or any combination thereof. Further, the term aryl includes fused and non-fused rings containing from six to about twelve ring carbon atoms, as well as those containing from six to about ten ring carbon atoms. A non-limiting example of a single ring aryl group includes phenyl; a fused ring aryl group includes naphthyl, phenanthrenyl, anthracenyl, azulenyl; and a non-fused bi-aryl group includes biphenyl.

20 **[0055]** The term “arylene” as used herein, alone or in combination, refers to a diradical derived from the above-defined monoradical, aryl. Examples include, but are not limited to 1, 2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene and the like.

[0056] The term “heteroaryl” as used herein, alone or in combination, refers to optionally substituted aromatic monoradicals containing from about five to about twenty skeletal ring atoms,

25 where one or more of the ring atoms is a heteroatom independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but not limited to these atoms and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Where two or more heteroatoms are present in the ring, in some embodiments, the two or more heteroatoms are the same as each another; in some embodiments, some or all of the two or more heteroatoms are be different

from the others. The term heteroaryl includes optionally substituted fused and non-fused heteroaryl radicals having at least one heteroatom. The term heteroaryl also includes fused and non-fused heteroaryls having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms. In some embodiments, bonding to a heteroaryl group is via a carbon atom; in some embodiments, via a heteroatom. Thus, as a non-limiting example, an imidazole group is attached to a parent molecule via any of its carbon atoms (imidazol-2-yl, imidazol-4-yl or imidazol-5-yl), or its nitrogen atoms (imidazol-1-yl or imidazol-3-yl). Further, in some embodiments, a heteroaryl group is substituted via any or all of its carbon atoms, and/or any or all of its heteroatoms. A fused heteroaryl radical contains from two to four fused rings, where the ring of attachment is a heteroaromatic ring. In some embodiments, the other individual rings are alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. A non-limiting example of a single ring heteroaryl group includes pyridyl; fused ring heteroaryl groups include benzimidazolyl, quinolinyl, acridinyl; and a non-fused bi-heteroaryl group includes bipyridinyl. Further examples of heteroaryls include, without limitation, furanyl, thienyl, oxazolyl, acridinyl, phenazinyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, benzoxadiazolyl, benzotriazolyl, imidazolyl, indolyl, isoxazolyl, isoquinolinyl, indoliziny, isothiazolyl, isoindoloxadiazolyl, indazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrazinyl, pyrazolyl, purinyl, phthalazinyl, pteridinyl, quinolinyl, quinazolinyl, quinoxalinyl, triazolyl, tetrazolyl, thiazolyl, triazinyl, thiadiazolyl and the like, and their oxides, such as for example pyridyl-N-oxide. Illustrative examples of heteroaryl groups include the following moieties:



[0057] The term “heteroarylene” as used herein, alone or in combination, refers to a diradical derived from the above-defined monoradical heteroaryl. Examples include, but are not limited to pyridinyl and pyrimidinyl.

[0058] The term “heterocyclyl” as used herein, alone or in combination, refers collectively to heteroalicyclyl and heteroaryl groups. Herein, whenever the number of carbon atoms in a heterocycle is indicated (e.g., C₁-C₆ heterocycle), at least one non-carbon atom (the heteroatom) must be present in the ring. Designations such as “C₁-C₆ heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. Designations such as “4-6 membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e.,

a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). For heterocycles having two or more heteroatoms, in some embodiments, those two or more heteroatoms are the same; in some embodiments, they are different from one another. In some
5 embodiments, heterocycles are substituted. Non-aromatic heterocyclic groups include groups having only three atoms in the ring, while aromatic heterocyclic groups must have at least five atoms in the ring. In some embodiments, bonding (i.e. attachment to a parent molecule or further substitution) to a heterocycle is via a heteroatom; in some embodiments, via a carbon atom.

[0059] The term “carbocyclyl” as used herein, alone or in combination, refers collectively to
10 alicyclyl and aryl groups; i.e. all carbon, covalently closed ring structures. In some embodiments, the carbocyclyl is saturated, partially unsaturated, fully unsaturated or aromatic. In some embodiments, carbocyclic rings are formed by three, carbon atoms; in some embodiments, four carbon atoms; in some embodiments, five carbon atoms; in some embodiments, six carbon atoms; in some embodiment, seven carbon atoms; in some embodiments, eight carbon atoms; in some
15 embodiments, nine carbon atoms; in some embodiments, more than nine carbon atoms. Carbocycles are optionally substituted. The term distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one atom which is different from carbon.

[0060] The terms “halogen”, “halo” or “halide” as used herein, alone or in combination refer to fluoro, chloro, bromo and iodo.

20 **[0061]** The term “hydroxy” as used herein, alone or in combination, refers to the monoradical -OH.

[0062] The term “cyano” as used herein, alone or in combination, refers to the monoradical -CN.

[0063] The term “cyanomethyl” as used herein, alone or in combination, refers to the monoradical -CH₂CN.

[0064] The term “nitro” as used herein, alone or in combination, refers to the monoradical -NO₂.

25 **[0065]** The term “oxy” as used herein, alone or in combination, refers to the diradical -O-.

[0066] The term “oxo” as used herein, alone or in combination, refers to the diradical =O.

[0067] The term “carbonyl” as used herein, alone or in combination, refers to the diradical -C(=O)-, which is also written as -C(O)-.

[0068] The terms “carboxy” or “carboxyl” as used herein, alone or in combination, refer to the
30 moiety -C(O)OH, which is alternatively written as -COOH.

[0069] The term “alkoxy” as used herein, alone or in combination, refers to an alkyl ether radical, -O-alkyl, including the groups -O-aliphatic and -O-carbocyclyl, wherein the alkyl, aliphatic and carbocyclyl groups are optionally substituted, and wherein the terms alkyl, aliphatic and carbocyclyl are as defined herein. Non-limiting examples of alkoxy radicals include methoxy, ethoxy, n-
35 propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

[0070] The term “sulfinyl” as used herein, alone or in combination, refers to the diradical -S(=O)-.

[0071] The term “sulfonyl” as used herein, alone or in combination, refers to the diradical $-S(=O)_2-$.

[0072] The terms “sulfonamide”, “sulfonamido” and “sulfonamidyl” as used herein, alone or in combination, refer to the diradical groups $-S(=O)_2-NH-$ and $-NH-S(=O)_2-$.

[0073] The terms “sulfamide”, “sulfamido” and “sulfamidyl” as used herein, alone or in combination, refer to the diradical group $-NH-S(=O)_2-NH-$.

[0074] It is to be understood that in instances where two or more radicals are used in succession to define a substituent attached to a structure, the first named radical is considered to be terminal and the last named radical is considered to be attached to the structure in question. Thus, for example, the radical arylalkyl is attached to the structure in question by the alkyl group.

Certain Pharmaceutical Terminology

[0075] The term “subject”, “patient” or “individual” as used herein in reference to individuals suffering from a disorder, and the like, encompasses mammals and non-mammals. Mammals are any member of the Mammalian class, including but not limited to humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In some embodiments of the methods and compositions provided herein, the subject is a mammal. In preferred embodiments, the subject is a human.

[0076] The terms “treat,” “treating” or “treatment,” and other grammatical equivalents as used herein, include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis. The terms further include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that, in some embodiments, the patient is still afflicted with the underlying disorder. For prophylactic benefit, the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even if a diagnosis of the disease has not been made.

[0077] The terms “administer,” “administering”, “administration,” and the like, as used herein, refer to the methods that are used to enable delivery of compounds or compositions to the desired

site of biological action. These methods include, but are not limited to oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion), topical and rectal administration. In preferred embodiments, the compounds and compositions described herein are administered orally.

5 [0078] The terms “effective amount”, “therapeutically effective amount” or “pharmaceutically effective amount” as used herein, refer to a sufficient amount of at least one agent or compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. In some embodiments, the result is a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For
10 example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease. In some embodiments, the “effective” amount differs from one individual to another. In some embodiments, an appropriate “effective” amount is determined using any suitable technique (e.g., a dose escalation study).

15 [0079] The term “acceptable” as used herein, with respect to a formulation, composition or ingredient, means having no persistent detrimental effect on the general health of the subject being treated.

[0080] The term “pharmaceutically acceptable” as used herein, refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of a compound disclosed
20 herein, and is relatively nontoxic (i.e., when the material is administered to an individual it does not cause undesirable biological effects nor does it interact in a deleterious manner with any of the components of the composition in which it is contained).

[0081] The term “prodrug” as used herein, refers to a drug precursor that, following administration to a subject and subsequent absorption, is converted to an active, or a more active species via some
25 process, such as conversion by a metabolic pathway. Thus, the term encompasses any derivative of a compound, which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or a pharmaceutically active metabolite or residue thereof. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved
30 and/or modified from the prodrug the active drug is generated. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g. by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g. the brain or lymphatic system).

35 [0082] The term “pharmaceutically acceptable salt” as used herein, refers to salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not

biologically or otherwise undesirable. In some embodiments, a compound disclosed herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared *in situ* during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.

[0083] The term “pharmaceutical composition,” as used herein, refers to a biologically active compound, optionally mixed with at least one pharmaceutically acceptable chemical component, such as, though not limited to carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, excipients and the like.

[0084] The term “carrier” as used herein, refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.

[0085] The terms “pharmaceutical combination”, “administering an additional therapy”, “administering an additional therapeutic agent” and the like, as used herein, refer to a pharmaceutical therapy resulting from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of a compound or composition disclosed herein. The term “fixed combination” means that at least one of a compound disclosed herein, and at least one co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that at least one of a compound disclosed herein, and at least one co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with variable intervening time limits, wherein such administration provides effective levels of the two or more compounds in the body of the patient. These also apply to cocktail therapies, e.g. the administration of three or more active ingredients.


[0086] The terms “co-administration”, “administered in combination with” and their grammatical equivalents or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different times. In some embodiments, a compound disclosed herein will be co-administered with other agents. These terms encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. They include simultaneous administration in separate compositions, administration at different times in separate compositions, and/or administration in a composition in which both agents are present. Thus, in some embodiments, the compounds of the invention and the other agent(s) are administered in a single composition. In some embodiments, compounds of the invention and the other agent(s) are admixed in the composition.

[0087] The term “metabolite,” as used herein, refers to a derivative of a compound which is formed when the compound is metabolized.

[0088] The term “active metabolite,” as used herein, refers to a biologically active derivative of a compound that is formed when the compound is metabolized.


5 [0089] The term “metabolized,” as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. In some embodiments, enzymes produce structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated
10 glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphhydryl groups. Further information on metabolism is found in *The Pharmacological Basis of Therapeutics*, 9th Edition, McGraw-Hill (1996).

Compounds



15 [0090] Disclosed herein are compounds of Formula (I): (I) wherein

R^1 is an electron lone pair, H, Br, Cl, Br, I, NH_2 , methyl, ethyl, *n*-propyl, *i*-propyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted *n*-propyl, optionally substituted *i*-propyl, CF_3 , CHF_2 or CH_2F ;



20 R^2 is wherein each R^{4a} and R^{4b} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; or R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N; each R^{4c} and R^{4d} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H ,
25 ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; R^P is H, methyl, ethyl, propyl, *i*-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or CN;


R^3 is $-X-CR^{5a}R^{5b}-(CR^{6a}R^{6b})_n-C(O)-O-R^M$ wherein X is S or O; each R^{5a} , R^{5b} , R^{6a} and R^{6b} is independently selected from H, F, Cl, Br, CH_3 and CF_3 ; n is 0 or 1; and R^M is H, a

pharmaceutically acceptable cation, substituted or unsubstituted (C₁₋₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a prodrug moiety;


Ar is a 5-membered aromatic heterocycle comprising from one to four heteroatoms each independently selected from O, N and S; and

5 wherein the groups R¹, R² and R³ are immediately adjacent to each other.


[0091] In specific embodiments, Ar is a pyrrole, a pyrazole, an imidazole, a triazole, a tetrazole, an oxazole, a thiazole, an isoxazole, an isothiazole, an oxadiazole or a thiadiazole. In some embodiments, Ar is a pyrrole of Formula (II-A), (II-B), (II-C) or (II-D):




(II-A)



(II-B)




(II-C)




(II-D)

or a tautomer thereof.


[0092] In other specific embodiments, R¹ is H and Ar is a pyrrole of Formula (III-A), (III-B), (III-C) or (III-D):




(III-A)



(III-B)




(III-C)




(III-D)

or a tautomer thereof.


[0093] In some embodiments, Ar is a pyrazole or an imidazole of Formula (IV-A), (IV-B), (IV-C), (IV-D) or (IV-E):




(IV-A)




(IV-B)



(IV-C)




(IV-D)




(IV-E)

or a tautomer thereof.

[0094] In some embodiments, Ar is a triazole of Formula (V-A) or (V-B):




(V-A)



(V-B)

or a tautomer thereof.

[0095] In some embodiments, R¹ is H and Ar is a tetrazole of Formula (VI):




(VI)


or a tautomer thereof.

[0096] In some embodiments, Ar is an oxazole, a thiazole, an isoxazole or an isothiazole of


5 Formula (VII-A), (VII-B), (VII-C) or (VII-D):




(VII A)



(VII B)



(VII C)




(VII D)


or a tautomer thereof.

[0097] In some embodiments, R¹ is H and Ar is an oxazole, a thiazole, an isoxazole or an


10 isothiazole of Formula (VIII-A), (VIII-B), (VIII-C), (VIII-D), (VIII-E), (VIII-F), (VIII-G), (VIII-H), (VIII-I), (VIII-J), (VIII-K) or (VIII-L):




(VIII-A)




(VIII-B)




(VIII-C)




(VIII-D)




(VIII-E)




(VIII-F)




(VIII-G)




(VIII-H)




(VIII-I)



(VIII-J)



(VIII-K)




(VIII-L)


or a tautomer thereof.

[0098] In some embodiments, R¹ is H and Ar is an oxadiazole or a thiadiazole of Formula (IX-A),


20 (IX-B), (IX-C), (IX-D), (IX-E) or (IX-F):




(IX-A)




(IX-B)




(IX-C)



(IX-D)




(IX-E)



(IX-F)


or a tautomer thereof.

[0099] In some embodiments, R^1 is an electron lone pair. In some embodiments, R^1 is H. In some embodiments, R^1 is Br.



[00100] In some embodiments, R^2 is: R^P .

[00101] In some embodiments, R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N.



[00102] In some embodiments, R^2 is R^P .

[00103] In some embodiments, R^P is cyclopropyl or CN.

[00104] In some embodiments, X is O. In some embodiments, X is S.

10 [00105] In some embodiments, n is 0. In some embodiments, n is 1.


[00106] In some embodiments, R^{5a} is H and R^{5b} is H. In some embodiments, R^{5a} is F and R^{5b} is F.

[00107] In some embodiments, n is 0, R^{5a} is H and R^{5b} is H. In some embodiments, n is 0, R^{5a} is F and R^{5b} is F.

15 [00108] In some embodiments, R^M is H. In some embodiments, R^M is a pharmaceutically acceptable cation.

[00109] In some embodiments, n is 0, R^{5a} is F and R^{5b} is F.


[00110] Disclosed herein, in certain embodiments, is a method of inhibiting a URAT-1 transporter,



comprising contacting the URAT-1 transporter with a compound of Formula (I):

wherein:

20 R^1 is an electron lone pair, H, Br, Cl, Br, I, NH_2 , methyl, ethyl, *n*-propyl, *i*-propyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted *n*-propyl, optionally substituted *i*-propyl, CF_3 , CHF_2 or CH_2F ;



R^2 is R^P wherein each R^{4a} and R^{4b} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; or R^{4a} and R^{4b} , together with the carbon atoms to which

25

they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N; each R^{4c} and R^{4d} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; R^P is H, methyl, ethyl, propyl, *i*-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or CN;

R^3 is $-X-CR^{5a}R^{5b}-(CR^{6a}R^{6b})_n-C(O)-O-R^M$ wherein X is S or O; each R^{5a} , R^{5b} , R^{6a} and R^{6b} is independently selected from H, F, Cl, Br, CH_3 and CF_3 ; n is 0 or 1; and R^M is H, a pharmaceutically acceptable cation, substituted or unsubstituted (C_{1-6}) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a prodrug moiety;

Ar is a 5-membered aromatic heterocycle comprising from one to four heteroatoms each independently selected from O, N and S; and

wherein the groups R^1 , R^2 and R^3 are immediately adjacent to each other.

Synthetic Procedures

[00111] In another aspect, methods for synthesizing a compound disclosed herein are provided. A compound disclosed herein is prepared by any of the methods described below. The procedures and examples below are intended to illustrate those methods. Neither the procedures nor the examples should be construed as limiting the invention in any way. A compound disclosed herein is also synthesized using standard synthetic techniques or using such methods in combination with methods described herein.

[00112] In some embodiments, the starting materials used for the synthesis of the compounds as described herein are obtained from commercial sources, such as Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co. (St. Louis, Mo.). In some embodiments, the starting materials are synthesized.

[00113] A compound disclosed herein, and other related compounds having different substituents is synthesized using any suitable technique, such as described, for example, in March, ADVANCED ORGANIC CHEMISTRY 4th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosures). The various moieties found in the formulae as provided herein are obtained using any suitable method. The following synthetic methods serve as a guide for synthesizing a compound disclosed herein.

Formation of Covalent Linkages by Reaction of an Electrophile with a Nucleophile

[00114] In some embodiments, a compound disclosed herein is modified using various electrophiles or nucleophiles to form new functional groups or substituents. The table below entitled “Examples of Covalent Linkages and Precursors Thereof” lists selected examples of covalent linkages and precursor functional groups. Precursor functional groups are shown as electrophilic groups and

5 nucleophilic groups.

Covalent Linkage Product	Electrophile	Nucleophile
Carboxamides	Activated esters	Amines/anilines
Carboxamides	Acyl azides	Amines/anilines
Carboxamides	Acyl halides	Amines/anilines
Esters	Acyl halides	Alcohols/phenols
Esters	Acyl nitriles	Alcohols/phenols
Carboxamides	Acyl nitriles	Amines/anilines
Imines	Aldehydes	Amines/anilines
Hydrazones	Aldehydes or ketones	Hydrazines
Oximes	Aldehydes or ketones	Hydroxylamines
Alkyl amines	Alkyl halides	Amines/anilines
Esters	Alkyl halides	Carboxylic acids
Thioethers	Alkyl halides	Thiols
Ethers	Alkyl halides	Alcohols/phenols
Thioethers	Alkyl sulfonates	Thiols
Esters	Alkyl sulfonates	Carboxylic acids
Ethers	Alkyl sulfonates	Alcohols/phenols
Esters	Anhydrides	Alcohols/phenols
Carboxamides	Anhydrides	Amines/anilines
Thiophenols	Aryl halides	Thiols
Aryl amines	Aryl halides	Amines
Thioethers	Aziridines	Thiols
Boronate esters	Boronates	Glycols
Carboxamides	Carboxylic acids	Amines/anilines
Esters	Carboxylic acids	Alcohols
Hydrazines	Hydrazides	Carboxylic acids
<i>N</i> -acylureas or Anhydrides	Carbodiimides	Carboxylic acids
Esters	Diazoalkanes	Carboxylic acids
Thioethers	Epoxides	Thiols
Thioethers	Haloacetamides	Thiols
Ammotriazines	Halotriazines	Amines/anilines
Triazinyl ethers	Halotriazines	Alcohols/phenols
Amidines	Imido esters	Amines/anilines
Ureas	Isocyanates	Amines/anilines
Urethanes	Isocyanates	Alcohols/phenols
Thioureas	Isothiocyanates	Amines/anilines
Thioethers	Maleimides	Thiols
Phosphite esters	Phosphoramidites	Alcohols
Silyl ethers	Silyl halides	Alcohols
Alkyl amines	Sulfonate esters	Amines/anilines
Thioethers	Sulfonate esters	Thiols
Esters	Sulfonate esters	Carboxylic acids
Ethers	Sulfonate esters	Alcohols

Sulfonamides	Sulfonyl halides	Amines/anilines
Sulfonate esters	Sulfonyl halides	Phenols/alcohols

Examples of Covalent Linkages and Precursors Thereof

Use of Protecting Groups


[00115] In some embodiments, it is necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Protecting groups are used to block some or all reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. It is preferred that each protective group be removable by a different means. Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal. In some embodiments, protective groups are removed by acid, base, hydrogenolysis, or combinations thereof. In some embodiments, groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile. In some embodiments, carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butyl carbamate or with carbamates that are both acid and base stable but hydrolytically removable.

[00116] In some embodiments, carboxylic acid and hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group. In some embodiments, amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc. In some embodiments, carboxylic acid reactive moieties are protected by conversion to simple ester compounds as exemplified herein. In some embodiments, carboxylic acid reactive moieties are blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups are blocked with fluoride labile silyl carbamates.

[00117] In some embodiments, allyl blocking groups are used in the presence of acid- and base-protecting groups since the former are stable. In some embodiments, allyl blocking groups are subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid is deprotected with a Pd-catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups.

[00118] In some embodiments, the protecting group is a resin to which a compound or intermediate is attached. In certain instances, as long as the residue is attached to the resin, the functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.


[00119] In some embodiments, the protecting group is:



[00120] Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosures.

Preparing compounds of Formula (I)

[00121] In some embodiments, compounds of Formula (I), $(R^1)R^2\text{-Ar-X-CR}^{5a}R^{5b}\text{-(CR}^{6a}R^{6b})_n\text{-C(O)OR}^M$, are prepared according to the general scheme below, starting from the alcohol $(R^1)R^2\text{-Ar-OH}$ or thiol $(R^1)R^2\text{-Ar-SH}$, employing protecting groups as needed:



[00122] In some embodiments, alcohol (X = O) or thiol (X = S), $(R^1)R^2\text{-Ar-XH}$ is directly alkylated with an α -haloacetic acid in the presence of base or, via a two step process. In some embodiments, where protection of the acid group is required $(R^1)R^2\text{-Ar-XH}$ is alkylated with an α -haloacetic ester, and then converted to $(R^1)R^2\text{-Ar-X-CR}^{5a}R^{5b}\text{-(CR}^{6a}R^{6b})_n\text{-C(O)OH}$ by hydrolysis of the ester protecting group.

[00123] In some embodiments, optional treatment of the resulting acid with an aqueous solution of metal hydroxide results in formation of the corresponding salt (R^M is not H), $(R^1)R^2-Ar-X-CR^{5a}R^{5b}-(CR^{6a}R^{6b})_n-C(O)OR^M$.

5 *Further Forms*

Isomers

[00124] In some embodiments, a compound disclosed herein exists as geometric isomers. In some embodiments, a compound disclosed herein possesses one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as
10 the corresponding mixtures thereof.

[00125] In some embodiments, compounds disclosed herein exist as tautomers. A compound disclosed herein includes all possible tautomers within the formulas described herein. In some embodiments, a compound disclosed herein possesses one or more chiral centers. In some embodiments, each center exists in the R or S configuration. A compound disclosed herein includes
15 all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.

[00126] In some embodiments, a compound disclosed herein is prepared as their individual
20 stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, resolution of enantiomers is carried out using covalent diastereomeric derivatives of a compound disclosed herein. In some embodiments, resolution of enantiomers is carried out using dissociable complexes (e.g., crystalline diastereomeric
25 salts). In certain instances, diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.). In some embodiments, diastereomers are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any
30 practical means that would not result in racemization.

Labeled compounds

[00127] In some embodiments, a compound disclosed herein exists in its isotopically-labeled forms. The invention provides for methods of treating diseases by administering such isotopically-labeled
35 compounds. The invention further provides for methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, compounds of formula I also

include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Isotopes for use with a method or compound disclosed herein include, but are not limited to, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chloride, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. A compound disclosed herein, and the metabolites, pharmaceutically acceptable salts, esters, prodrugs, solvate, hydrates or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i. e., ^3H and carbon-14, i. e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. In some embodiments, substitution with heavy isotopes (e.g., deuterium, i. e., ^2H) is utilized with a method or compound disclosed herein. In certain instances, substitution with heavy isotopes affords certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, a compound, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof is isotopically labeled by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent in any procedure disclosed herein.

[00128] In some embodiments, a compound described herein is labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

Metabolites

[00129] In some embodiments, a compound disclosed herein exists as a metabolite. The invention provides for methods of treating diseases by administering such metabolites. The invention further provides for methods of treating diseases by administering such metabolites as pharmaceutical compositions.

[00130] In some embodiments, a compound disclosed herein is metabolized by a variety of metabolic mechanisms, such as hydrolysis, oxidation, glycolysis, phosphorylation, alkylation, dehalogenation, or combinations thereof.

Pharmaceutically acceptable salts

[00131] In some embodiments, a compound disclosed herein exists as a pharmaceutically acceptable salt. The invention provides for methods of treating diseases by administering such pharmaceutically acceptable salts. The invention further provides for methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[00132] In some embodiments, a compound disclosed herein possesses an acidic or basic group. In some embodiments, a compound disclosed herein that possesses an acidic or basic group reacts with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, a salt is prepared *in situ* during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.

[00133] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of a compound disclosed herein with a mineral, organic acid or inorganic base, such salts including, acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ -hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate undeconate and xylenesulfonate.

[00134] Further, a compound disclosed herein is optionally prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, Q-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, are optionally employed in the preparation of

salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[00135] In some embodiments, a compound disclosed herein which comprises a free acid group reacts with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, $N^+(C_{1-4} \text{ alkyl})_4$, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It should be understood that a compound disclosed herein also includes the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization. A compound disclosed herein is optionally prepared as pharmaceutically acceptable salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, for example an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. In some embodiments, base addition salts are also prepared by reacting the free acid form of a compound disclosed herein with a pharmaceutically acceptable inorganic or organic base, including, but not limited to organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like and inorganic bases such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. In addition, the salt forms of the disclosed compounds are optionally prepared using salts of the starting materials or intermediates.

Solvates

[00136] In some embodiments, a compound disclosed herein exists as a solvate. The invention provides for methods of treating diseases by administering such solvates. The invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.

[00137] In certain instances, solvates contain either stoichiometric or non-stoichiometric amounts of a solvent. In some embodiments, a solvate is formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In some embodiments, a solvate of a compound disclosed herein is prepared or formed during the processes described herein. By way of example only, hydrates of a compound disclosed herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not

limited to, dioxane, tetrahydrofuran or methanol. In some embodiments, a compound provided herein exists in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.

5 Polymorphs

[00138] In some embodiments, a compound disclosed herein exists as a polymorph. The invention provides for methods of treating diseases by administering such polymorphs. The invention further provides for methods of treating diseases by administering such polymorphs as pharmaceutical compositions.

10 [00139] Thus, a compound disclosed herein includes all crystalline forms, known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. In certain instances, polymorphs have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. In certain instances, varying the recrystallization solvent, rate of crystallization,
15 storage temperature, or a combination thereof results in a single crystal form dominating.

Prodrugs

[00140] In some embodiments, a compound disclosed herein exists as a prodrug. The invention provides for methods of treating diseases by administering such prodrugs. The invention further
20 provides for methods of treating diseases by administering such prodrugs as pharmaceutical compositions.

[00141] As used herein, a “prodrugs” is a drug precursor that, following administration to a subject and subsequent absorption, is converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug
25 that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated.

[00142] In certain instances, prodrugs are useful as they easier to administer than the parent drug. In certain instances, a prodrug is bioavailable by oral administration whereas the parent is not. In some embodiments, a prodrug has improved solubility in pharmaceutical compositions over the parent
30 drug. An example, without limitation, of a prodrug would be a compound as described herein which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug is a short peptide (polyamino acid) bonded to an acid group where the peptide
35 is metabolized to reveal the active moiety.

[00143] Various forms of prodrugs include those found, for example in Bundgaard, "Design and Application of Prodrugs" in *A Textbook of Drug Design and Development*, Krosgaard-Larsen and Bundgaard, Ed., 1991, Chapter 5, 113-191, which is incorporated herein by reference for such disclosures.

5 [00144] In some embodiments, prodrugs are designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues. The design of prodrugs to date has been to increase the effective water solubility of the therapeutic compound for targeting to regions where water is the principal solvent.

[00145] Additionally, prodrug derivatives of a compound disclosed herein are prepared by methods
10 such as those described in Saulnier *et al.*, *Bioorganic and Medicinal Chemistry Letters*, 1994, 4, 1985). By way of example only, appropriate prodrugs are prepared by reacting a non-derivatized compound with a suitable carbamylating agent, such as, but not limited to, 1,1-acyloxyalkylcarbanochloridate, *para*-nitrophenyl carbonate, or the like. Prodrug forms of a compound disclosed herein, wherein the prodrug is metabolized *in vivo* to produce a derivative as
15 set forth herein, are included within the scope of the claims. In some embodiments, some of the herein-described compounds are prodrugs for another derivative or active compound.


[00146] In some embodiments, prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e. g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of
20 the present invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone. In other embodiments, prodrugs include compounds wherein a nucleic acid residue, or an oligonucleotide of two or more (e. g., two, three or four)
25 nucleic acid residues is covalently joined to a compound of the present invention.

[00147] Pharmaceutically acceptable prodrugs of a compound disclosed herein also include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, metal salts and sulfonate esters. In some embodiments, compounds having free
30 amino, amido, hydroxy or carboxylic groups are converted into prodrugs. For instance, free carboxyl groups are derivatized as amides or alkyl esters. In some embodiments, a prodrug moiety incorporates groups including but not limited to ether, amine and carboxylic acid functionalities.

[00148] Hydroxy prodrugs include esters, such as though not limited to, acyloxyalkyl (e.g. acyloxymethyl, acyloxyethyl) esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters,
35 phosphate esters, sulfonate esters, sulfate esters and disulfide containing esters; ethers, amides,

carbamates, hemisuccinates, dimethylaminoacetates and phosphoryloxymethyloxycarbonyls, as outlined in *Advanced Drug Delivery Reviews* 1996, 19, 115.

[00149] Amine derived prodrugs include, but are not limited to the following groups and combinations of groups:



as well as sulfonamides and phosphonamides.

[00150] In certain instances, sites on any aromatic ring portions are susceptible to various metabolic reactions. In some embodiments, incorporation of appropriate substituents on the aromatic ring structures reduces, minimizes or eliminates this metabolic pathway.

Pharmaceutical compositions

[00151] Described herein are pharmaceutical compositions. In some embodiments, the pharmaceutical compositions comprise an effective amount of a compound of formula I, or a metabolite, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In some embodiments, the pharmaceutical compositions comprise an effective amount of a compound of formula I, or a metabolite, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof and at least one pharmaceutically acceptable carrier. In some embodiments the pharmaceutical compositions are for the treatment of disorders. In some embodiments the pharmaceutical compositions are for the treatment of disorders in a mammal. In some embodiments the pharmaceutical compositions are for the treatment of disorders in a human.

Formulations

[00152] A compound or composition described herein is administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. Administration of a compound or composition described herein is effected by any method that enables delivery of the compounds to the site of action. These methods include, though are not limited to delivery via enteral routes (including oral, gastric or duodenal feeding tube, rectal suppository and rectal enema), parenteral routes (injection or infusion, including intraarterial, intracardiac, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalational, transdermal, transmucosal, sublingual, buccal and topical

(including epicutaneous, dermal, enema, eye drops, ear drops, intranasal, vaginal) administration. In some embodiments, the most suitable route depends upon the condition and disorder of the recipient. By way of example only, a compound disclosed herein is administered locally to the area in need of treatment by local infusion during surgery, topical application (e.g., as a cream or ointment),

5 injection (e.g., directly into the site of a diseased tissue or organ), catheter, or implant.

[00153] In some embodiments, a formulation suitable for oral administration is presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of a compound or composition disclosed herein; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid

10 emulsion. In some embodiments, a compound or composition disclosed herein is presented as a bolus, electuary or paste.

[00154] Pharmaceutical preparations for oral administration include tablets, solutions, suspension, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In some embodiments, dye or pigment is added to an oral dosage form

15 for identification or to characterize different doses.

[00155] In some embodiments, a tablet is made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, a compressed tablet is prepared by compressing in a suitable machine a compound or composition disclosed herein in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. In some embodiments, a molded tablet is made by molding in a suitable machine

20 a mixture of the powdered compound moistened with an inert liquid diluent. In some embodiments, a tablet disclosed herein is coated or scored. In some embodiments, a tablet disclosed herein is formulated so as to provide slow or controlled release of a compound or composition disclosed herein therein. In some embodiments, a tablet disclosed herein further comprises an excipient. In some embodiments, a tablet disclosed herein further comprises inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. In some embodiments, a

25 composition comprising a compound disclosed herein further comprises a sweetening agent, flavoring agent, coloring agent, or preserving agents.

[00156] In some embodiments, a compound or composition disclosed herein is formulated as a hard gelatin capsule. In some embodiments, a compound or composition disclosed herein is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin.

[00157] In some embodiments, a push-fit capsule contains a compound or composition disclosed herein in admixture with a filler (e.g., lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers).

[00158] In some embodiments, a soft capsule comprises a compound or composition disclosed herein dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, a stabilizer is added. In some embodiments, a compound or composition disclosed herein is mixed with a water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[00159] In some embodiments, a dragee core is provided with suitable coatings. In some embodiments, concentrated sugar solutions are used. In some embodiments, the sugar solution comprises gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

[00160] In some embodiments, a compound or composition disclosed herein is formulated as an aqueous suspension. In some embodiments, a compound or composition disclosed herein further comprises a suspending agent, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; or a dispersing or wetting agent (e.g., a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. In some embodiments, a compound or composition disclosed herein further comprises a preservative, for example ethyl, or n-propyl p-hydroxybenzoate; a coloring agent; a flavoring agents; a sweetening agent, such as sucrose, saccharin or aspartame; or combinations thereof.

[00161] In some embodiments, a compound or composition disclosed herein is formulated as an oily suspension. In some embodiments, an oily suspension is formulated by suspending a compound or composition disclosed herein in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. In some embodiments, a composition or compound disclosed herein further comprises a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. In some embodiments, a composition or compound disclosed herein further comprises a sweetening agent, a flavoring agent, or a combination thereof. In some embodiments, a composition or compound disclosed herein further comprises an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.

[00162] In some embodiments, a compound or composition disclosed herein is formulated as an oil-in-water emulsion. In some embodiments, the oily phase is a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. In some embodiments, an oil-in-water emulsion comprises an emulsifying agent. In some embodiments, the emulsifying agent is a naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. In some embodiments, a composition disclosed herein further comprises a sweetening agent, flavoring agent, preservative, or antioxidant.

[00163] In some embodiments, a composition or compound disclosed herein is formulated as a syrup or elixir. In some embodiments, a syrup or elixir further comprises a sweetening agent, for example glycerol, propylene glycol, sorbitol or sucrose. In some embodiments, a syrup or elixir further comprises a demulcent, a preservative, a flavoring agent, a coloring agent, and antioxidant, or a combination thereof.

[00164] In some embodiments, a compound or composition disclosed herein is formulated for parenteral administration (e.g., by bolus injection or continuous infusion). In some embodiments, a formulation for parenteral administration comprises suspending agents (fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes), thickening agents (e.g., sodium carboxymethyl cellulose, sorbitol, or dextran), stabilizing agents, dispersing agents, or combinations thereof. In some embodiments, a formulation for parenteral administration further comprises an antioxidant, buffer, bacteriostat, solute which render the formulation isotonic with blood, or a combination thereof. In some embodiments, a formulation for injection further comprises a preservative.

[00165] In some embodiments, a formulation for parenteral administration is an aqueous solution. In some embodiments, a formulation for parenteral administration comprises water, Ringer's solution, or isotonic sodium chloride solution.

[00166] In some embodiments, a formulation for parenteral administration is in the form of an oil-in-water micro-emulsion where a compound or composition disclosed herein is dissolved in the oily phase. In some embodiments, the oily phase comprises a mixture of soybean oil and lecithin. In some embodiments, the oily phase is introduced into a water and glycerol mixture and processed to form a microemulsion.

[00167] In some embodiments, a formulation for parenteral administration is administered into a patient's blood-stream by local bolus injection. In some embodiments, a continuous intravenous delivery device is utilized. An example of such a device is the Deltec CADD-PLUS™ model 5400 intravenous pump.

[00168] In some embodiments, a formulation for parenteral administration is presented in unit-dose or multi-dose containers, for example sealed ampoules and vials. In some embodiments, a formulation for parenteral administration is stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, prior to use. In some embodiments, a formulation for parenteral administration extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.

[00169] In some embodiments, a compound or composition disclosed herein is formulated as a depot preparation. In some embodiments, a depot preparation is administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In some embodiments, a compound or composition disclosed herein is formulated with any suitable polymeric or hydrophobic material (e.g., emulsion in an acceptable oil), ion exchange resin. In some embodiments, a compound disclosed herein is formulated as a sparingly soluble derivatives, for example, as a sparingly soluble salt.

[00170] In some embodiments, a compound or composition disclosed herein is formulated for buccal or sublingual administration. In some embodiments, a compound or composition disclosed herein is in the form of a tablet, lozenge, pastille, or gel. In some embodiments, formulation for buccal or sublingual administration further comprises a flavoring agent (e.g., sucrose, acacia, or tragacanth).

[00171] In some embodiments, a compound or composition disclosed herein is formulated for rectal administration (e.g., as a suppository or retention enema). In some embodiments, a compound or composition disclosed herein is formulated as a suppository. In some embodiments, a rectal formulation comprises a non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature. In some embodiments, a rectal formulation comprises cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

[00172] In some embodiments, a compound or composition disclosed herein is administered topically, that is by non-systemic administration. In some embodiments, a compound or composition disclosed herein is administered to the epidermis or the buccal cavity. In some embodiments, a compound or composition disclosed herein is formulated as a gel, liniment, lotion, cream, ointment, paste, or solution (e.g., as drops suitable for administration to the eye, ear or nose). In some embodiments, compound disclosed herein comprises from about 0.001% to 10% w/w of a topical formulation. In some embodiments, compound disclosed herein comprises from about 1% to 2% by weight of a topical formulation. In some embodiments, compound disclosed herein comprises about 10% w/w of a topical formulation; preferably, less than 5% w/w; more preferably from 0.1% to 1% w/w.

[00173] In some embodiments, a pharmaceutical formulation for administration by inhalation is delivered from an insufflator, nebulizer pressurized packs or other means of delivering an aerosol spray. In some embodiments, a pressurized pack comprises a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, or carbon dioxide). In some embodiments, a device for administering an inhalable formulation comprises a meter. In some
5 embodiments, a pharmaceutical formulation for administration by inhalation is in the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. In some embodiments, the powder composition is presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder is administered
10 with the aid of an inhalator or insufflator.

[00174] It should be understood that in addition to the ingredients particularly mentioned above, the compounds and compositions described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

Doses

[00175] The amount of pharmaceutical composition administered will firstly be dependent on the individual being treated. In the instances where pharmaceutical compositions are administered to a human, the daily dosage will normally be determined by the prescribing physician with the dosage
20 generally varying according to the age, sex, diet, weight, general health and response of the individual patient, the severity of the patient's symptoms, the precise indication or condition being treated, the severity of the indication or condition being treated, time of administration, route of administration, the disposition of the composition, rate of excretion, drug combination, and the discretion of the prescribing physician. In some embodiments, treatment is initiated with smaller
25 dosages which are less than the optimum dose of the compound; thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. In some embodiments, the total daily dosage is divided and administered in portions. The amount and frequency of administration of a compound disclosed herein, and if applicable other therapeutic agents and/or therapies, will be regulated according to the judgment of the attending clinician
30 (physician).

[00176] In some embodiments, the dosage is between about 0.001 mg/kg of body weight to about 100 mg/kg of body weight per day (administered in single or divided doses), more preferably at least about 0.1 mg/kg of body weight per day. In some embodiments, the dosage is from about 0.01 mg to about 7000 mg of compound, and preferably includes, e.g., from about 0.05 mg to about 2500 mg.
35 In some embodiments, the dosage is from about 0.1 mg to 1000 mg, preferably from about 1 mg to 300 mg, more preferably 10 mg to 200 mg, according to the particular application. In some

instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day. The amount administered will vary depending on the particular IC_{50} value of the compound used. In
5 combinational applications in which the compound is not the sole therapy, it may be possible to administer lesser amounts of compound and still have therapeutic or prophylactic effect.

Combination Therapies

[00177] In some embodiments, a compound or composition disclosed herein is administered as a
10 sole therapy. In some embodiments, a compound or composition disclosed herein is administered in combination with an additional active agent.

[00178] In some embodiments, the therapeutic effectiveness of a compound disclosed herein is enhanced by administration of an adjuvant. In some embodiments, the benefit experienced by an individual is increased by administering a compound or composition disclosed herein with another
15 therapeutic agent. In some embodiments, the therapeutic effectiveness of a compound disclosed herein is enhanced by administration of physiotherapy, psychotherapy, radiation therapy, application of compresses to a diseased area, rest, altered diet, and the like.


[00179] By way of example only, in a treatment for gout the therapeutic effectiveness of a compound disclosed herein is increased by also providing the patient with another therapeutic agent
20 for gout. Or, by way of example only, if one of the side effects experienced by a patient upon receiving one of a compound disclosed herein is nausea, then an anti- nausea agent is administered in combination with the compound.

[00180] In some embodiments, a compound disclosed herein is not administered in the same pharmaceutical composition as the additional therapeutic agent. In some embodiments, a compound
25 disclosed herein is administered by a different route from the additional therapeutic agent. For example, a compound or composition disclosed herein is administered orally, while the additional therapeutic agent is administered intravenously.

[00181] In some embodiments, a compound or composition disclosed herein and an additional therapeutic agent (or additional therapy) are administered concurrently (e.g., simultaneously,
30 essentially simultaneously or within the same treatment protocol), sequentially or dosed separately.

[00182] The particular choice of compound and other therapeutic agent will depend upon the diagnosis of the attending physicians and their judgment of the condition of the individual and the appropriate treatment protocol. In some embodiments, the additional agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, a purine
35 nucleoside phosphorylase (PNP) inhibitor, a uric acid transporter inhibitor, a glucose transporter (GLUT) inhibitor, a GLUT-9 inhibitor, a solute carrier family 2 (facilitated glucose transporter),

member 9 (SLC2A9) inhibitor, an organic anion transporter (OAT) inhibitor, an OAT-4 inhibitor, or combinations thereof. In certain instances, URAT 1 is an ion exchanger that mediates urate transportation. In certain instances, URAT I mediates urate transportation in the proximal tubule. In certain instances, URAT I exchanges urate in a proximal tubule for lactate and nicotinate. In certain instances, xanthine oxidase oxidizes hypoxanthine to xanthine, and further to uric acid. In certain instances, xanthine dehydrogenase catalyzes the conversion of xanthine, NAD^+ , and H_2O into urate, NADH , and H^+ . In some embodiments, the additional agent is allopurinol, febuxostat (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid), FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile), probenecid, sulfinpyrazone, benzbromarone, acetaminophen, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), adrenocorticotrophic hormone (ACTH), colchicine, a glucocorticoid, an androgen, a cox-2 inhibitor, a PPAR agonist, naproxen, sevelamer, sibutmaine, troglitazone, proglitazone, another uric acid lowering agent, losartan, fibric acid, benziadarone, salicylate, amlodipine, vitamin C, or combinations thereof.



Diseases

[00183] Described herein are methods of treating a disease in an individual suffering from said disease comprising administering to said individual an effective amount of a composition comprising a compound disclosed herein or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[00184] Also described herein are methods of preventing or delaying onset of a disease in an individual at risk for developing said disease comprising administering to said individual an effective amount to prevent or delay onset of said disease, of a composition comprising a compound disclosed herein or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

[00185] Further described herein are methods for the prophylaxis or treatment of any disease or disorder in which aberrant levels of uric acid plays a role including, without limitation:

hyperuricemia, gout, gouty arthritis, inflammatory arthritis, kidney disease, nephrolithiasis (kidney stones), joint inflammation, deposition of urate crystals in joints, urolithiasis (formation of calculus in the urinary tract), deposition of urate crystals in renal parenchyma, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, gout flare, tophaceous gout, kidney failure, or combinations thereof in a human or other mammal. The methods disclosed herein extend to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders. Further, the

methods disclosed herein extend to the administration to a human an effective amount of a compound disclosed herein for treating any such disease or disorder.

[00186] Individuals that can be treated with the compounds described herein, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative of said compounds, according to the methods of this invention include, for example, individuals that have been diagnosed as having gout, 5 gouty arthritis, inflammatory arthritis, kidney disease, nephrolithiasis (kidney stones), joint inflammation, deposition of urate crystals in joints, urolithiasis (formation of calculus in the urinary tract), deposition of urate crystals in renal parenchyma, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, gout flare, tophaceous gout, kidney failure, or combinations thereof.

[00187] In some embodiments, an individual having an aberrant uric acid level is administered an amount of at least one compound disclosed herein sufficient to modulate the aberrant uric acid level (e.g., to a medically-acceptable level). In some embodiments, an individual treated with the compounds disclosed herein displays aberrant uric acid levels wherein the uric acid levels in blood exceed a medically-accepted range (i.e., hyperuricemia). In some embodiments, an individual 15 treated with the compounds disclosed herein displays aberrant uric acid levels wherein uric acid levels in the blood exceed 360 $\mu\text{mol/L}$ (6 mg/dL) for a female individual or 400 $\mu\text{mol/L}$ (6.8 mg/dL) for a male individual. In some embodiments, an individual treated with the compounds disclosed herein displays aberrant uric acid levels wherein uric acid levels in urine exceed a medically-accepted range (i.e., hyperuricosuria). In some embodiments, an individual treated with the 20 compounds disclosed herein displays aberrant uric acid levels wherein uric acid levels in urine exceed 800 mg/day (in a male individual) and greater than 750 mg/day (in a female individual).

[00188] In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from a cardiovascular disorder. In some 25 embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from an aneurysm; angina; atherosclerosis; a stroke; cerebrovascular disease; congestive heart failure; coronary artery disease; and/or a myocardial infarction. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) displays (a) c-reactive protein (CRP) levels above about 3.0 mg/L; (b) homocysteine levels above about 15,9 $\mu\text{mol/L}$; (c) LDL levels above about 160 mg/dL; (d) HDL 30 levels below about 40 mg/dL; and/or (e) serum creatinine levels above about 1.5 mg/dL.

[00189] In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from diabetes. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from Type I diabetes. In some embodiments, an individual treated with the compounds disclosed 35 herein (1) displays aberrant uric acid levels, and (2) suffers from Type II diabetes. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric


acid levels, and (2) suffers from a loss of beta cells of the islets of Langerhans in the pancreas. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from insulin resistance and/or reduced insulin sensitivity. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) displays (a) a fasting plasma glucose level ≥ 126 mg/dL; (b) a plasma glucose level ≥ 200 mg/dL two hours after a glucose tolerance test; and/or (c) symptoms of hyperglycemia and casual plasma glucose levels ≥ 200 mg/dL (11.1 mmol/l).

[00190] In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from metabolic syndrome. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from (a) diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and/or insulin resistance, (b) at least two of (i) blood pressure: $\geq 140/90$ mmHg; (ii) dyslipidaemia: triglycerides (TG): ≥ 1.695 mmol/L and high-density lipoprotein cholesterol (HDL-C) ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female); (iii) central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), and/or body mass index > 30 kg/m²; and (iv) microalbuminuria: urinary albumin excretion ratio ≥ 20 mg/min or albumin:creatinine ratio ≥ 30 mg/g. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from insulin resistance (i.e., the top 25% of the fasting insulin values among non-diabetic individuals) and (b) at least two of (i) central obesity: waist circumference ≥ 94 cm (male), ≥ 80 cm (female); (ii) dyslipidaemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated for dyslipidaemia; (iii) hypertension: blood pressure $\geq 140/90$ mmHg or antihypertensive medication; and (iv) fasting plasma glucose ≥ 6.1 mmol/L. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) displays at least three of (a) elevated waist circumference: Men ≥ 40 inches (men) and ≥ 35 inches (women); (b) elevated triglycerides: ≥ 150 mg/dL; (c) reduced HDL: < 40 mg/dL (men) and < 50 mg/dL (women); (d) elevated blood pressure: $\geq 130/85$ mm Hg or use of medication for hypertension; and (e) elevated fasting glucose: ≥ 100 mg/dL (5.6 mmol/L) or use of medication for hyperglycemia.


[00191] In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) suffers from kidney disease or kidney failure. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) displays oliguria (decreased urine production. In some embodiments, an individual treated with the compounds disclosed herein (1) displays aberrant uric acid levels, and (2) produces less than 400 mL per day of urine (adults), produces less than 0.5 mL/kg/h of urine (children), or produces less than 1 mL/kg/h of urine (infants).

Uric Acid

[00192] In certain instances, purines (adenine, guanine), derived from food or tissue turnover (cellular nucleotides undergo continuous turnover), are catabolized in humans to their final oxidation product, uric acid. In certain instances, guanine is oxidized to xanthine, which is turn is further oxidized to uric acid by the action of xanthine oxidase; adenosine is converted to inosine which is further oxidized to hypoxanthine. In certain instances, xanthine oxidase oxidizes hypoxanthine to xanthine, and further to uric acid. In certain instances, as part of the reverse process, the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) salvages guanine and hypoxanthine.



[00193] In certain instances, the keto form of uric acid is in equilibrium with the enol form which loses a proton at physiological pH to form urate. In certain instances, (e.g., under serum conditions (pH 7.40, 37°C)), about 98% of uric acid is ionized as the monosodium urate salt. In certain instances, urate is a strong reducing agent and potent antioxidant. In humans, about half the antioxidant capacity of plasma comes from uric acid.



[00194] In certain instances, most uric acid dissolves in blood and passes to the kidneys, where it is excreted by glomerular filtration and tubular secretion. In certain instances, a substantial fraction of uric acid is reabsorbed by the renal tubules. One of the peculiar characteristics of the uric acid transport system is that, although the net activity of tubular function is reabsorption of uric acid, the molecule is both secreted and reabsorbed during its passage through the nephron. In certain instances, reabsorption dominates in the S1 and S3 segments of the proximal tubule and secretion dominates in the S2 segment. In certain instances, the bidirectional transport results in drugs that inhibit uric acid transport decreasing, rather than increasing, the excretion of uric acid, compromising their therapeutic usefulness. In certain instances, normal uric acid levels in human adults (5.1 +/- 0.93 mg/dL) are close to the limits of urate solubility (~7 mg/dL at 37°C), which creates a delicate physiologic urate balance. In certain instances, the normal uric acid range for females is approximately 1 mg/dL below the male range.

Hyperuricemia

[00195] In certain instances, hyperuricemia is characterized by higher than normal blood levels of uric acid, sustained over long periods of time. In certain instances, increased blood urate levels may be due to enhanced uric acid production (~10-20%) and/or reduced renal excretion (~80-90%) of uric acid. In certain instances, causes of hyperuricemia may include:

- Obesity/weight gain
- Excessive alcohol use
- Excessive dietary purine intake (foods such as shellfish, fish roe, scallops, peas lentils, beans and red meat, particularly offal - brains, kidneys, tripe, liver)
- Certain medications, including low-dose aspirin, diuretics, niacin, cyclosporine, pyrazinamide, ethambutol, some high blood pressure drugs and some cancer chemotherapeutics, immunosuppressive and cytotoxic agents
- Specific disease states, particularly those associated with a high cell turnover rate (such as malignancy, leukemia, lymphoma or psoriasis), and also including high blood pressure, hemoglobin disorders, hemolytic anemia, sickle cell anemia, various nephropathies, myeloproliferative and lymphoproliferative disorders, hyperparathyroidism, renal disease, conditions associated with insulin resistance and diabetes mellitus, and in transplant recipients, and possibly heart disease
- Inherited enzyme defects
- Abnormal kidney function (e.g. increased ATP turn over, reduced glomerular urate filtration)
- Exposure to lead (plumbism or “saturnine gout”)

[00196] In certain instances, hyperuricemia may be asymptomatic, though is associated with the following conditions: Gout, Gouty arthritis, Uric acid stones in the urinary tract (urolithiasis), Deposits of uric acid in the soft tissue (tophi), Deposits of uric acid in the kidneys (uric acid nephropathy), and Impaired kidney function, possibly leading to chronic and acute renal failure.

Gout**Prevalence**

[00197] The incidence of gout has increased over the past two decades and, in the United States, affects as much as 2.7% of the population aged 20 years and older, totaling over 5.1 million American adults. Gout is more common in men than women, (3.8% or 3.4 million men vs. 1.6% or 1.7 million women), typically affecting men in their 40's and 50's (although gout attacks can occur after puberty which sees an increase in uric acid levels). An increase in prevalence of gout from 2.9 to 5.2 per 1000 in the time period 1990 to 1999 was observed, with most of the increase occurring in those over the age of 65. Gout attacks are more common in women after menopause. In certain

instances, gout is one of the most common forms of arthritis, accounting for approximately 5% of all arthritis cases. In certain instances, kidney failure and urolithiasis occur in 10-18% of individuals with gout and are common sources of morbidity and mortality from the disease.

Leading causes

5 [00198] In most cases, gout is associated with hyperuricemia. In certain instances, individuals suffering from gout excrete approximately 40% less uric acid than nongouty individuals for any given plasma urate concentrations. In certain instances, urate levels increase until the saturation point is reached. In certain instances, precipitation of urate crystals occurs when the saturation point is reached. In certain instances, these hardened, crystallized deposits (tophi) form in the joints and
10 skin, causing joint inflammation (arthritis). In certain instances, deposits are made in the joint fluid (synovial fluid) and/or joint lining (synovial lining). Common areas for these deposits are the large toe, feet, ankles and hands (less common areas include the ears and eyes). In certain instances, the skin around an affected joint becomes red and shiny with the affected area being tender and painful to touch. In certain instances, gout attacks increase in frequency. In certain instances,
15 untreated acute gout attacks lead to permanent joint damage and disability. In certain instances, tissue deposition of urate leads to: acute inflammatory arthritis, chronic arthritis, deposition of urate crystals in renal parenchyma and urolithiasis. In certain instances, the incidence of gouty arthritis increases 5 fold in individuals with serum urate levels of 7 to 8.9 mg/dL and up to 50 fold in individuals with levels > 9mg/dL (530 μ mol/L). In certain instances, individuals with gout develop
20 renal insufficiency and end stage renal disease (i.e., "gouty nephropathy"). In certain instances, gouty nephropathy is characterized by a chronic interstitial nephropathy, which is promoted by medullary deposition of monosodium urate.

[00199] In certain instances, gout includes painful attacks of acute, monarticular, inflammatory arthritis, deposition of urate crystals in joints, deposition of urate crystals in renal parenchyma,
25 urolithiasis (formation of calculus in the urinary tract), and nephrolithiasis (formation of kidney stones). In certain instances, secondary gout occurs in individuals with cancer, particularly leukemia, and those with other blood disorders (e.g. polycythemia, myeloid metaplasia, etc).

Symptoms

[00200] In certain instances, attacks of gout develop very quickly, frequently the first attack
30 occurring at night. In certain instances, symptoms include sudden, severe joint pain and extreme tenderness in the joint area, joint swelling and shiny red or purple skin around the joint. In certain instances, the attacks are infrequent lasting 5-10 days, with no symptoms between episodes. In certain instances, attacks become more frequent and may last longer, especially if the disorder is not controlled. In certain instances, episodes damage the affected joint(s) resulting in stiffness, swelling,
35 limited motion and/or persistent mild to moderate pain.


Treatment

[00201] In certain instances, gout is treated by lowering the production of uric acid. In certain instances, gout is treated by increasing the excretion of uric acid. In certain instances, gout is treated by URAT 1, xanthine oxidase, xanthine dehydrogenase, xanthine oxidoreductase, a purine nucleoside phosphorylase (PNP) inhibitor, a uric acid transporter (URAT) inhibitor, a glucose transporter (GLUT) inhibitor, a GLUT-9 inhibitor, a solute carrier family 2 (facilitated glucose transporter), member 9 (SLC2A9) inhibitor, an organic anion transporter (OAT) inhibitor, an OAT-4 inhibitor, or combinations thereof. In general, the goals of gout treatment are to i) reduce the pain, swelling and duration of an acute attack, and ii) prevent future attacks and joint damage. In certain instances, gout attacks are treated successfully using a combination of treatments. In certain instances, gout is one of the most treatable forms of arthritis.

[00202] *i) Treating the gout attack.* In certain instances, the pain and swelling associated with an acute attack of gout can be addressed with medications such as acetaminophen, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), adrenocorticotrophic hormone (ACTH) or colchicine. In certain instances, proper medication controls gout within 12 to 24 hours and treatment is stopped after a few days. In certain instances, medication is used in conjunction with rest, increased fluid intake, ice-packs, elevation and/or protection of the affected area/s. In certain instances, the aforementioned treatments do not prevent recurrent attacks and they do not affect the underlying disorders of abnormal uric acid metabolism.

[00203] *ii) Preventing future attacks.* In certain instances, reducing serum uric acid levels below the saturation level is the goal for preventing further gout attacks. In some cases, this is achieved by decreasing uric acid production (e.g. allopurinol), or increasing uric acid excretion with uricosuric agents (e.g. probenecid, sulfinpyrazone, benzbromarone).

[00204] In certain instances, *allopurinol* inhibits uric acid formation, resulting in a reduction in both the serum and urinary uric acid levels and becomes fully effective after 2 to 3 months.



In certain instances, allopurinol is a structural analogue of hypoxanthine, (differing only in the transposition of the carbon and nitrogen atoms at positions 7 and 8), which inhibits the action of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine, and xanthine to uric acid. In certain instances, it is metabolized to the corresponding xanthine analogue, alloxanthine (oxypurinol), which is also an inhibitor of xanthine oxidase. In certain instances, alloxanthine, though more potent in inhibiting xanthine oxidase, is less pharmaceutically acceptable due to low oral bioavailability. In certain instances, fatal reactions due to hypersensitivity, bone marrow suppression, hepatitis, and vasculitis have been reported with Allopurinol. In certain instances, the incidence of side effects may total 20% of all individuals treated with the drug.

Treatment for disorders of uric acid metabolism has not evolved significantly in the following two decades since the introduction of allopurinol.

[00205] In certain instances, *Uricosuric agents* (e.g., probenecid, sulfinpyrazone, and benzbromarone) increase uric acid excretion. In certain instances, probenecid causes an increase in uric acid secretion by the renal tubules and, when used chronically, mobilizes body stores of urate. In certain instances, 25-50% of individuals treated with probenecid fail to achieve reduction of serum uric acid levels < 6 mg/dL. In certain instances, insensitivity to probenecid results from drug intolerance, concomitant salicylate ingestion, and renal impairment. In certain instances, one-third of the individuals develop intolerance to probenecid. In certain instances, administration of uricosuric agents also results in urinary calculus, gastrointestinal obstruction, jaundice and anemia.

Plumbism or "Saturnine Gout"

[00206] In certain instances, excessive exposure to lead (lead poisoning or plumbism) results in "saturnine gout," a lead-induced hyperuricemia due to lead inhibition of tubular urate transport causing decreased renal excretion of uric acid. In certain instances, more than 50% of individuals suffering from lead nephropathy suffer from gout. In certain instances, acute attacks of saturnine gout occur in the knee more frequently than the big toe. In certain instances, renal disease is more frequent and more severe in saturnine gout than in primary gout. In certain instances, treatment consists of excluding the individual from further exposure to lead, the use of chelating agents to remove lead, and control of acute gouty arthritis and hyperuricaemia. In certain instances, saturnine gout is characterized by less frequent attacks than primary gout. In certain instances, lead-associated gout occurs in pre-menopausal women, an uncommon occurrence in non lead-associated gout.

Lesch-Nyhan Syndrome

[00207] In certain instances, Lesch-Nyhan syndrome (LNS or Nyhan's syndrome) affects about one in 100,000 live births. In certain instances, LNS is caused by a genetic deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). In certain instances, LNS is an X-linked recessive disease. In certain instances, LNS is present at birth in baby boys. In certain instances, the disorder leads to severe gout, poor muscle control, and moderate mental retardation, which appear in the first year of life. In certain instances, the disorder also results in self-mutilating behaviors (e.g., lip and finger biting, head banging) beginning in the second year of life. In certain instances, the disorder also results in gout-like swelling in the joints and severe kidney problems. In certain instances, the disorder leads neurological symptoms include facial grimacing, involuntary writhing, and repetitive movements of the arms and legs similar to those seen in Huntington's disease. The prognosis for individuals with LNS is poor. In certain instances, the life expectancy of

an untreated individual with LNS is less than about 5 years. In certain instances, the life expectancy of a treated individual with LNS is greater than about 40 years of age.

Hyperuricemia and Other Diseases

5 **[00208]** In certain instances, hyperuricemia is found in individuals with cardiovascular disease (CVD) and/or renal disease. In certain instances, hyperuricemia is found in individuals with prehypertension, hypertension, increased proximal sodium reabsorption, microalbuminuria, proteinuria, kidney disease, obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, hyperinsulinemia, hyperleptinemia, hypoadiponectinemia, peripheral, carotid and coronary artery
10 disease, atherosclerosis, congenative heart failure, stroke, tumor lysis syndrome, endothelial dysfunction, oxidative stress, elevated renin levels, elevated endothelin levels, and/or elevated C-reactive protein levels. In certain instances, hyperuricemia is found in individuals with obesity (e.g., central obesity), high blood pressure, hyperlipidemia, and/or impaired fasting glucose. In certain instances, hyperuricemia is found in individuals with metabolic syndrome. In certain instances,
15 gouty arthritis is indicative of an increased risk of acute myocardial infarction. In some embodiments, administration of the compounds described herein to an individual are useful for decreasing the likelihood of a clinical event associated with a disease or condition linked to hyperuricemia, including, but not limited to, prehypertension, hypertension, increased proximal sodium reabsorption, microalbuminuria, proteinuria, kidney disease, obesity, hypertriglyceridemia,
20 low high-density lipoprotein cholesterol, hyperinsulinemia, hyperleptinemia, hypoadiponectinemia, peripheral, carotid and coronary artery disease, atherosclerosis, congenative heart failure, stroke, tumor lysis syndrome, endothelial dysfunction, oxidative stress, elevated renin levels, elevated endothelin levels, and/or elevated C-reactive protein levels.

[00209] In some embodiments, the compounds described herein are administered to an individual
25 suffering from a disease or condition requiring treatment with a compound that is a diuretic. In some embodiments, the compounds described herein are administered to an individual suffering from a disease or condition requiring treatment with a compound that is a diuretic, wherein the diuretic causes renal retention of urate. In some embodiments, the disease or condition is congestive heart failure or essential hypertension.

30 **[00210]** In some embodiments, administration of the compounds described herein to an individual are useful for improving motility or improving quality of life.

[00211] In some embodiments, administration of the compounds described herein to an individual is useful for treating or decreasing the side effects of cancer treatment.

35 **[00212]** In some embodiments, administration of the compounds described herein to an individual is useful for decreasing kidney toxicity of cis-platin.

EXAMPLES

[00213] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.

I Chemical Syntheses

Example 1A: General synthetic procedure for alkylation of $(R^1)R^2$ -Ar-SH





[00214] Pyridine (10.3 mmol, 1.1eq) and aryl thiol (9.38 mmol, 1eq) are added to a solution of methyl 2-bromoacetate (10.3 mmol, 1.1eq) in DMSO (50mL). The solution is stirred at room temperature for 2h, diluted with ethyl acetate (300mL), washed successively with water (2×250mL) and brine (100mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude ester is dissolved in THF, aqueous sodium hydroxide solution (1N) added and the mixture stirred at room temperature for 30 min. The THF is removed under reduced pressure and the resulting residue dissolved in aqueous sodium hydroxide solution (1N). The solution is slowly acidified to pH2 at 0°C, by addition of aqueous HCl solution (1N). The resulting suspension is filtered and the isolated solid rinsed with water and dried under reduced pressure to give the alkylated product.

Example 1B: General synthetic procedure for salt formation of $(R^1)R^2$ -Ar-X- $CR^{5a}R^{5b}$ -($CR^{6a}R^{6b}$)_n-C(O)O⁻ M⁺


[00215] Aqueous metal hydroxide solution (1M, 2.0mL, 2.0mmol, 1eq) is added dropwise over 5 mins to a solution of acid (2.0mmol, 1eq) in ethanol (10mL) at 10°C and the mixture stirred at 10°C for a further 10 mins. Volatile solvents are removed *in vacuo* to dryness to provide the metal salt.


Example 2: Compounds of Formula (II-A), (II-B), (II-C) and (II-D)

[00216] Compounds of Formula (II-A), (II-B), (II-C) and (II-D) are compounds of Formula (I), wherein Ar is pyrrole:




Example 2A:

[00217] Compounds of Formula (II-A),  can be prepared according to the general scheme below:




5 **Example 2B:**

[00218] Compounds of Formula (II-B),  can be prepared according to the general scheme below:



10 **Example 2B-1: 2-(5-Methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid**



Step A: 2-Methyl-3-(naphthalen-1-yl)-1H-pyrrole

[00219] 1-(Naphthalen-1-yl)propan-2-one is treated with 2-chloroacetamide and potassium *tert*-butoxide in DMSO, and heated according to published procedures. The resulting pyrrolinone is reduced by treatment with 9-BBN in toluene at elevated temperatures (see Verniest, *et al*, *Synlett*, **2003**, 13, 2013-2017), to afford 2-methyl-3-(naphthalen-1-yl)-1H-pyrrole.

Step B: 2-Methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole

[00220] Triisopropylsilyl chloride is added to a mixture of *n*-BuLi and 2-methyl-3-(naphthalen-1-yl)-1H-pyrrole in THF at -78°C and the mixture allowed to warm to room temperature. 2-Methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole is isolated, purified if required and used in the next step.

Step C: 4-Bromo-2-methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole

[00221] 2-Methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole is brominated by treatment with NBS, (see Bray *et al*, *J. Org. Chem.*, **1990**, 55, 6317-6328 or Carmona *et al*, *J. Org. Chem.*, **1980**, 45 (26), 5336-5339) to afford 4-bromo-2-methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole.

Step D: Ethyl 2-(5-methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetate


[00222] 4-Bromo-2-methyl-3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole is treated with ⁿBuLi (1eq) and TMEDA (1eq) in THF at -78°C for 1 hr, to achieve lithium-halogen exchange, and the lithide is then treated with (iPrSiS)₂ (1eq) at -78°C to room temperature over 2 hr, to provide the thio derivative. Removal of the protecting group in the presence of ethyl bromoacetate, by adding ethyl bromoacetate (2.5eq) in toluene/DMF (1/1) at 0°C, and then adding TBAF (2.5eq in toluene) and reacting for 30mins affords ethyl 2-(5-methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetate.

Step E: 2-(5-Methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid

[00223] A mixture of ethyl 2-(5-methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetate, sodium hydroxide and methanol is stirred at reflux for 2 hours. The reaction is then cooled to room and the methanol removed. Water is added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer is dried over sodium sulfate, filtered, concentrated and purified by preparative thin layer chromatography (95% DCM/5% MeOH) to provide 2-(5-Methyl-4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid.


Example 3: Compounds of Formula (III-A), (III-B), (III-C) and (III-D)

[00224] Compounds of Formula (III-A), (III-B), (III-C) and (III-D) are compounds of Formula (I), wherein R¹ is H and Ar is a pyrrole:




Example 3D:

[00225] Compounds of Formula (III-D), , can be prepared according to the general scheme below:



Example 3D-1: 2-(4-(Naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid



Step A: 3-(Naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole

[00226] 1-(Triisopropylsilyl)-1H-pyrrole is iodinated to 3-iodo-1-(triisopropylsilyl)-1H-pyrrole by treatment with N-iodosuccinimide, and then converted to the lithio species by reaction with tert-butyl lithium in THF at -78°C, which is then converted to 1-(triisopropylsilyl)-1H-pyrrol-3-ylboronic acid, via treatment with trimethyl borate followed by hydrolysis.

Tetrakis(triphenylphosphine) palladium (0) catalysed coupling of the crude boronic acid with 1-iodonaphthalene provides 3-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole. (For additional details, see Alvarez et al, J. Org. Chem., 1992, 57, 1653-1656.)

Step B: 3-Bromo-4-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole

[00227] 3-(Naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole is brominated by treatment with PBr₃ (0.1eq) and NBS (1eq) in THF at -78°C for 1h and then room temperature for 3 hrs.

Step C: Ethyl 2-(4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetate






[00228] 3-Bromo-4-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole is treated with nBuLi (1eq) and TMEDA (1eq) in THF at -78°C for 1 hr, to achieve lithium-halogen exchange, and the lithide is then treated with (iPrSiS)₂ (1eq) at -78°C to room temperature over 2 hr, to provide the thio derivative. Removal of the protecting group in the presence of ethyl bromoacetate, by adding ethyl bromoacetate (2.5eq) in toluene/DMF (1/1) at 0°C, and then adding TBAF (2.5eq in toluene) and reacting for 30mins affords 3-bromo-4-(naphthalen-1-yl)-1-(triisopropylsilyl)-1H-pyrrole.

Step D: 2-(4-(Naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid


[00229] A mixture of ethyl 2-(4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetate, sodium hydroxide and methanol is stirred at reflux for 2 hours. The reaction is then cooled to room and the methanol removed. Water is added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer is dried over sodium sulfate, filtered, concentrated and purified by preparative thin layer chromatography (95% DCM/5% MeOH) to provide 2-(4-(naphthalen-1-yl)-1H-pyrrol-3-ylthio)acetic acid.


Example 4: Compounds of Formula (IV-A), (IV-B), (IV-C), (IV-D) and (IV-E)

[00230] Compounds of Formula (IV-A), (IV-B), (IV-C), (IV-D) and (IV-E), are compounds of Formula (I), wherein Ar is a pyrazole or an imidazole:




Example 4A:

[00231] Compounds of Formula (IV-A),  can be prepared according to the general scheme below:



5 **Example 4A-1:** 2-(1-Methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetic acid



Step A: 1-Methyl-5-(naphthalen-1-yl)-1H-imidazole

[00232] 1-Methyl-1H-imidazole is coupled with 1-iodonaphthalene in a Pd-catalyzed reaction to form 1-methyl-5-(naphthalen-1-yl)-1H-imidazole, (see Bellina *et al*, *Tetrahedron*, **2008**, 64 (26), 6060-6072).

Step B: 4-Bromo-1-methyl-5-(naphthalen-1-yl)-1H-imidazole

[00233] 1-Methyl-5-(naphthalen-1-yl)-1H-imidazole is brominated by reaction of 1-Methyl-5-(naphthalen-1-yl)-1H-imidazole with NBS to form 4-bromo-1-methyl-5-(naphthalen-1-yl)-1H-imidazole.


15 **Step C:** Ethyl 2-(1-methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetate


[00234] 4-Bromo-1-methyl-5-(naphthalen-1-yl)-1H-imidazole is treated with *n*BuLi (1eq) and TMEDA (1eq) in THF at -78°C for 1 hr, to achieve lithium-halogen exchange, and the lithide is then treated with (*i*PrSiS)₂ (1eq) at -78°C to room temperature over 2 hr, to provide ethyl 2-(1-methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetate.

20 **Step D:** 2-(1-Methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetic acid

[00235] A mixture of ethyl 2-(1-methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetate, sodium hydroxide and methanol is stirred at reflux for 2 hours. The reaction is then cooled to room and the methanol removed. Water is added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer is dried over sodium sulfate, filtered, concentrated and purified by preparative thin layer chromatography (95% DCM/5% MeOH) to provide 2-(1-Methyl-5-(naphthalen-1-yl)-1H-imidazol-4-ylthio)acetic acid.


Example 4B:

[00236] Compounds of Formula (IV-B),  can be prepared according to the general scheme below:

**Example 4B-1:** 2-(5-(2-chloro-4-methylphenyl)-1-methyl-1H-pyrazol-4-ylthio)acetic acid

[00237] 2-(5-(2-chloro-4-methylphenyl)-1-methyl-1H-pyrazol-4-ylthio)acetic acid is prepared

5 according to previously described procedures (see US published patent application US 2005/0282907), outlined below.

Step A: 1-(2-Chloro-4-methylphenyl)-3-hydroxyprop-2-en-1-one

10 **[00238]** To a suspension of sodium methoxide (384 mg, 7.12 mmol) in THF (18mL) at room temperature is added ethyl formate (574.9μL, 7.12 mmol) followed by a solution of 2-chloro-4-methylacetophenone (1.00 g, 5.93 mmol) in THF (6.0mL). The reaction mixture is stirred at room temperature for 16 h, and then aqueous sodium hydroxide solution (1N, 60mL) added. The aqueous phase is washed with ether (2 x 2mL) and the organic extracts discarded. The aqueous phase is

15 acidified with aqueous HCl solution (1N, 65mL) and then extracted with ether (3 x 40mL). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give 1-(2-chloro-4-methylphenyl)-3-hydroxyprop-2-en-1-one.

Step B: 5-(2-Chloro-4-methylphenyl)-1H-pyrazole

20 **[00239]** Hydrazine hydrate (193.2μL, 6.20 mmol) is added dropwise to a cold (0°C) solution of 1-(2-chloro-4-methylphenyl)-3-hydroxyprop-2-en-1-one (1.11 g, 5.64 mmol) in ethanol (15.0mL). The cooling bath is then removed and the reaction mixture stirred at room temperature for 3 h. The mixture is concentrated under reduced pressure and the residue diluted in dichloromethane (150mL). The solution is washed with brine, dried over magnesium sulfate, filtered and concentrated under

25 reduced pressure. The crude product is purified by flash chromatography (dichloromethane:acetone, 95:5) to afford. 5-(2-chloro-4-methylphenyl)-1H-pyrazole.

Step C: 4-Bromo-5-(2-chloro-4-methylphenyl)-1H-pyrazole

[00240] A solution of bromine (198 μ L, 3.83 mmol) in dichloromethane (10mL) is added dropwise to a solution of 5-(2-chloro-4-methylphenyl)-1*H*-pyrazole (671 mg, 3.48 mmol) in dichloromethane (20mL) and stirred at room temperature for 1 h. The mixture is diluted with dichloromethane (60mL) and the resulting solution successively washed with water, aqueous saturated NaHCO₃ solution and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane:acetone, 95:5) to afford 4-bromo-5-(2-chloro-4-methylphenyl)-1*H*-pyrazole.

Step D: 4-Bromo-5-(2-chloro-4-methylphenyl)-1-methyl-1*H*-pyrazole

[00241] Sodium hydride (60% in oil, 59.9 mg, 1.50 mmol) is added to a cold (0°C) solution of 4-bromo-5-(2-chloro-4-methylphenyl)-1*H*-pyrazole (369.6 mg, 1.36 mmol) in DMF (5mL) and stirred at 0°C for 30 min. Methyl iodide (93.2 μ L, 1.50 mmol) is added, the mixture warmed to room temperature and stirred for 1 h. The reaction mixture is diluted with ethyl acetate (100mL), washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane:acetone, 95:5) to afford 4-bromo-5-(2-chloro-4-methylphenyl)-1-methyl-1*H*-pyrazole.

Step E: 5-(2-chloro-4-methylphenyl)-1-methyl-4-(triisopropylsilylthio)-1*H*-pyrazole

[00242] A solution of *n*-BuLi in hexane (2.5 M, 115.6 μ L, 288.9 μ mol) is added to a cold (-78°C) solution of 4-bromo-5-(2-chloro-4-methylphenyl)-1-methyl-1*H*-pyrazole (75.0 mg, 262 μ mol) in THF (4mL). After 15 min, a solution of (tPr₃SiS)₂ (199.0 mg, 525.3 μ mol) in THF (1mL) is added via cannula to the reaction mixture at -78°C. The reaction mixture is stirred for 15 min, the cooling bath removed and the solution stirred for a further 3 h. Dichloromethane (50mL) is added and the mixture washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to afford 5-(2-chloro-4-methylphenyl)-1-methyl-4-(triisopropylsilylthio)-1*H*-pyrazole.

Step F: tert-butyl 2-(5-(2-chloro-4-methylphenyl)-1-methyl-1*H*-pyrazol-4-ylthio)acetate


[00243] TBAF (1.0 M in THF, 294 μ L, 294 μ mol) is added to a solution of 5-(2-chloro-4-methylphenyl)-1-methyl-4-(triisopropylsilylthio)-1*H*-pyrazole (46.4 mg, 117 μ mol) and tert-butyl bromoacetate (43.4 μ L, 294 μ mol) in DMF (3mL) and stirred for 30 min. The reaction mixture is quenched with water (10mL) and diluted with ethyl acetate (60mL). The organic phase is washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane:acetone, 95:5) to afford 5-(2-chloro-4-methylphenyl)-1-methyl-4-(triisopropylsilylthio)-1*H*-pyrazole.


Step G: 2-(5-(2-chloro-4-methylphenyl)-1-methyl-1*H*-pyrazol-4-ylthio)acetic acid

[00244] Trifluoroacetic acid (TFA, 1.0mL, 13.0 mmol) is added dropwise to a solution of 5-(2-chloro-4-methylphenyl)-1-methyl-4-(triisopropylsilylthio)-1*H*-pyrazole (34.8 mg, 98.6 μ mol) in dichloromethane (2mL) at room temperature and stirred for 8 h. The mixture is concentrated under


reduced pressure and the crude product purified by RP-HPLC to afford 2-(5-(2-chloro-4-methylphenyl)-1-methyl-1H-pyrazol-4-ylthio)acetic acid.

Example 4D:

[00245] Compounds of Formula (IV-D),  can be prepared according to the general scheme below:



Example 4D-1: 2-Methyl-2-(1-(naphthalen-1-yl)-1H-pyrazol-5-yloxy)propanoic acid



Step A: Ethyl 5-hydroxy-1-(naphthalen-1-yl)-1H-pyrazole-4-carboxylate

[00246] To a mixture of naphthalen-1-ylhydrazine hydrochloride (1g, 5.1 mmol) and potassium carbonate (1.4g, 10.3 mmol) in water (30mL) was added diethyl ethoxymethylenemalonate (1.1g, 5.1 mmol) at room temperature. The reaction mixture was stirred for 3 hours at room temperature and then extracted with ethyl acetate. The aqueous layer was acidified with 1N HCl to pH 2 and then extracted with ethyl acetate again. This organic layer was dried over sodium sulfate and concentrated to give ethyl 5-hydroxy-1-(naphthalen-1-yl)-1H-pyrazole-4-carboxylate as a solid.

Step B: 1-(Naphthalen-1-yl)-1H-pyrazol-5-ol

[00247] A mixture of ethyl 5-hydroxy-1-(naphthalen-1-yl)-1H-pyrazole-4-carboxylate (480mg, 1.8 mmol), aqueous potassium hydroxide solution (35%, 2.2mL, 13.5 mmol) and methanol (5mL) was heated to reflux for 24 hours. The reaction mixture was then cooled to 0°C, acidified to pH 2 with conc. HCl and refluxed for additional 12 hours to complete decarboxylation. The reaction was then cooled to room temperature and concentrated. The residue was taken up in water and extracted with ethyl acetate, the organic layer washed with water, dried over sodium sulfate and concentrated. Purification by preparative TLC (95% dichloromethane/5% methanol) afforded 1-(naphthalen-1-yl)-1H-pyrazol-5-ol.

Step C: Ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1H-pyrazol-5-yloxy)propanoate

[00248] A mixture of 1-(naphthalen-1-yl)-1H-pyrazol-5-ol (250mg, 1.2 mmol), ethyl bromoisobutyrate (0.2mL, 1.3mmol) and potassium carbonate (318mg, 1.3 mmol) in DMF (3mL) was stirred at room temperature for 16 hours. Water was then added to the reaction mixture, extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by preparative


thin layer chromatography (95% dichloromethane/5% methanol) afforded ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-yloxy)propanoate as a solid.

Step D: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-yloxy)propanoic acid

[00249] A mixture of ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-yloxy)propanoate (80mg, 0.25 mmol), aqueous sodium hydroxide solution (10%, 5mL) and methanol (5mL) was stirred at reflux for 2 hours. The reaction was then cooled to room temperature and the methanol removed. Water was added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) afforded 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-yloxy)propanoic acid as a solid.

[00250] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.4 (s, 1H), 8.09 (m, 2H), 7.65 (m, 6H), 5.78 (d, 1H), 1.37 (s, 6H).

Example 4D-2: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoic acid



Step A: 1-(Naphthalen-1-yl)-1*H*-pyrazole

[00251] A mixture of 1*H*-pyrazole (300 mg, 4.4 mmol), iodonaphthalene (1.1g, 4.4 mmol), copper (I) iodide (126mg, 0.66 mmol), Cs₂CO₃ (2.15g, 6.6 mmol) in DMF (5mL) was evacuated and filled with nitrogen twice. The reaction was then stirred at room temperature for 30 minutes and then at 120°C for 2 days. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, filtered through silica gel and concentrated to give 1-(naphthalen-1-yl)-1*H*-pyrazole as pure solid. (800mg, 93%).

Step B: 1-(Naphthalen-1-yl)-1*H*-pyrazole-5-thiol

[00252] To a solution of 1-(Naphthalen-1-yl)-1*H*-pyrazole (796mg, 4.1 mmol) in THF (7mL) at -78°C was added n-BuLi (1.6M hexanes, 2.8mL, 4.5 mmol) and the mixture was stirred at -78°C for 30 minutes. Sulfur was then added (145 mg, 4.5 mmol) and the mixture was allowed to warm to °C and stirred for 7 hours at 0°C. Saturated aqueous ammonium chloride and 10% aqueous HCl was added and the mixture extracted with ethyl acetate. The organic layer was then extracted with a 5% aqueous potassium carbonate solution; the aqueous layer acidified with 10% HCl and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to give 1-(naphthalen-1-yl)-1*H*-pyrazole-5-thiol as a solid.

Step C: Ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoate

[00253] A mixture of 1-(naphthalen-1-yl)-1*H*-pyrazole-5-thiol (120 mg, 0.53 mmol), ethyl bromoisobutyrate (0.09mL, 0.58 mmol) and potassium carbonate (81mg, 0.58 mmol) in DMF (3mL)


was stirred at room temperature for 16 hours. Water was then added to the reaction mixture, extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% acetone) afforded ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoate as a solid. (124 mg, 69%).


Step D: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoic acid

[00254] A mixture of ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoate (124mg, 0.36 mmol), aqueous sodium hydroxide solution (10%, 5mL) and methanol (5mL) was stirred at reflux for 2 hours. The reaction was then cooled to room temperature and the methanol removed. Water was added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) afforded 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-pyrazol-5-ylthio)propanoic acid as a solid.


[00255] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.2 (s, 1H), 8.14 (m, 2H), 7.91 (s, 1H), 7.69 (m, 4H), 7.09 (d, *J* = 8.3 Hz, 1H), 6.79 (s, 1H), 1.21 (s, 6H).

Example 4E:

[00256] Compounds of Formula (IV-E),  can be prepared according to the general scheme below:



Example 4E-1: 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoic acid



Step A: Ethyl 2-(naphthalen-1-yl)-3-oxobutanoate

[00257] To a solution of ethyl 2-(naphthalen-1-yl)acetate (1g, 4.7 mmol) in tetrahydrofuran (20mL) at -78°C was added LiHMDS (1M THF, 9.4mL, 9.4 mmol) and the reaction mixture stirred at -78°C for 1 hour. Acetic anhydride was then added (0.54mL, 5.64 mmol) dropwise and the reaction allowed to warm to room temperature and stirred for 30 minutes. Aqueous HCl solution (1N, 25mL) was added to the reaction mixture and then extracted with ethyl acetate, dried over sodium sulfate and concentrated to give compound ethyl 2-(naphthalen-1-yl)-3-oxobutanoate as a light yellow oil, that was used in the next step without further purification.

Step B: 5-Methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-ol

[00258] A mixture of ethyl 2-(naphthalen-1-yl)-3-oxobutanoate (500 mg, 1.95 mmol) and hydrazine hydrate (0.122mL, 3.9 mmol) in ethanol (3mL) was stirred at reflux for 2 hours. The reaction mixture was then cooled to room temperature and concentrated to give compound methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-ol as an oil that solidified upon standing (400mg, 91%). The crude product was used in next step without further purification.

Step C: Ethyl 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoate

[00259] A mixture of 5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-ol (200mg, 0.89 mmol), ethyl bromoisobutyrate (0.14mL, 0.89 mmol) and potassium carbonate (136mg, 0.98 mmol) in DMF (3mL) was stirred at room temperature for 16 hours. Water was then added to the reaction mixture, extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) afforded compound ethyl 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoate as a solid.


Step D: 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoic acid

[00260] A mixture of ethyl 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoate (60mg, 0.18 mmol), aqueous sodium hydroxide solution (10%, 5mL) and methanol (5mL) was stirred at reflux for 2 hours. The reaction was then cooled to room and the methanol removed. Water was added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane /5% methanol) afforded compound 2-methyl-2-(5-methyl-4-(naphthalen-1-yl)-1*H*-pyrazol-3-yloxy)propanoic acid as a solid (40mg, 71%).


[00261] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.0 (s, 1H), 12.2 (s, 1H), 8.3 (d, J=8.0 Hz, 1H), 7.90 (d, J=7.8 Hz, 1H), 7.82 (d, J=8.1 Hz, 1H), 7.5 (m, 4H), 2.0 (s, 3H), 1.37 (s, 6H).


Example 5: Compounds of Formula (V-A) and (V-B)

[00262] Compounds of Formula (V-A) and (V-B) are compounds of Formula (I), wherein Ar is a triazole




Example 5A:

[00263] Compounds of Formula (V-A),  can be prepared according to the general scheme below:



[00264] R^2 -isocyanate is reacted with the trimethylsilyldiazomethane anion to form 1- R^1 -1*H*-1,2,3-triazole-5-thiol, which is alkylated with ethyl bromoacetate, which may be deprotected by hydrolysis of the ester to provide the desired triazole.

Example 5A-1: 2-(1-(naphthalen-1-yl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetic acid



Step A:


[00265] To a solution of (trimethylsilyl)diazomethane in hexane (2M, 1.74mL, 3.5 mmol) in tetrahydrofuran (10mL) at -78°C was added dropwise *n*-BuLi and the mixture was stirred at -78°C for 1 hour. Isothiocyanatobenzene (500 mg, 2.9 mmol) in THF (4mL) was added and the mixture was stirred at -78°C for 1 hour. Ethyl bromoacetate (484 mg, 2.9 mmol) was then added and the mixture was stirred at -78°C for 30 min. and then at 0°C for additional 30 min. Iced water was added to the reaction and the mixture was extracted with ether. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give ethyl 2-(1-(naphthalen-1-yl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetate as a yellow oil, that was used in the next step without further purification (1g, 89%).

Step B:

[00266] A mixture of compound ethyl 2-(1-(naphthalen-1-yl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetate (1g, 2.6 mmol), aqueous sodium hydroxide solution (10%, 12mL) and methanol (20mL) was stirred at reflux for 2 hours. The reaction mixture was then cooled to room temperature and concentrated to a reduced volume. Water was added, the reaction neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give 2-(1-(naphthalen-1-yl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetic acid as a solid.

[00267] ^1H NMR (DMSO- d_6 , 400MHz): δ 13.1 (s, 1H), 8.22 (d, $J=7.6$ Hz, 1H), 8.18 (d, $J=8.1$ Hz, 1H), 8.11 (s, 1H), 7.78 (m, 2H), 7.68 (m, 1H), 7.62 (m, 1H), 7.13 (d, $J=8.04$, 1H), 3.80 (s, 2H).

Example 5A-2: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-1,2,3-triazol-5-ylthio)propanoic acid




[00268] 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-1,2,3-triazol-5-ylthio)propanoic acid was prepared according to the same procedures described in example 5A-1, using 2-bromo-2-methylpropanoic acid in place of 2-bromoacetic acid.

- 5 **[00269]** ^1H NMR (DMSO- d_6 , 400MHz): δ 13.1 (s, 1H), 8.26 (d, $J=8.1$ Hz, 1H), 8.2 (s, 1H), 8.16 (d, $J=8.1$ Hz, 1H), 7.78 (m, 2H), 7.68 (m, 1H), 7.62 (m, 1H), 7.03 (d, $J=8.04$, 1H), 1.27 (s, 6H)

Example 5A-3: 2-(1-(2-Chloro-4-methylphenyl)-1*H*-1,2,3-triazol-5-ylthio)acetic acid

- 10 **[00270]** 2-(1-(2-Chloro-4-methylphenyl)-1*H*-1,2,3-triazol-5-ylthio)acetic acid is prepared according as outlined below.



Step A:

- 15 **[00271]** A solution of *n*-BuLi in hexane (2.5M, 5.23mL, 13.07 mmol) is added dropwise to a cold (-78°C) solution of (trimethylsilyl)diazomethane (2.0 M in hexane, 6.53mL, 13.07 mmol) in THF (50mL). After 20 min, a solution of 2-chloro-1-isothiocyanato-4-methylbenzene (2.0 g, 10.89 mmol) in THF (15mL) is added dropwise and the reaction mixture stirred at -78°C for 1 h. *tert*-Butyl bromoacetate (1.93mL, 13.07 mmol) is then added and the mixture stirred at -78°C for 30 min and then 0°C for another 30 min. Ice-water (50mL) and ether (300mL) are added and the mixture washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane / acetone 95 / 5) to afford *tert*-butyl 2-(1-(2-chloro-4-methylphenyl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetate.


Step B:

- 25 **[00272]** A mixture of *tert*-butyl 2-(1-(2-chloro-4-methylphenyl)-4-(trimethylsilyl)-1*H*-1,2,3-triazol-5-ylthio)acetate (1.0 g, 2.43 mmol) and aqueous KOH solution (10%, 12.5mL) in methanol (25mL) is heated under reflux for 2 h. The methanol is removed under reduced pressure and the mixture neutralized with aqueous HCl solution (1N). The aqueous phase is extracted with ether (2 x 10mL) and combined organic extracts washed with brine, dried over magnesium sulfate, filtered and

concentrated under reduced pressure to give 2-(1-(2-chloro-4-methylphenyl)-1*H*-1,2,3-triazol-5-ylthio)acetic acid.


Example 6: Compounds of Formula (VI)

- 5 **[00273]** Compounds of Formula (VI) are compounds of Formula (I), wherein R¹ is H and Ar is a tetrazole:




(VI)

[00274] Compounds of Formula (VI) can be prepared according to the general scheme below:



Example 6-1: 2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)acetic acid

[00275] 2-{{1-(1-Naphthalenyl)-1*H*-tetrazol-5-yl}thio}acetic acid can be prepared as described below.



- 15 **Step A:** 1-(Naphthalen-1-yl)-1*H*-tetrazole-5-thiol

[00276] To a solution of 1-naphthalenyliothiocyanate (500 mg, 2.7 mmol) in ethanol (150mL) was added sodium azide (2.8 g, 43 mmol) and the mixture was heated to 79°C for 2 hours. The reaction mixture was then cooled to room temperature, aqueous HCl solution (12N, 1.5mL) added and the mixture concentrated. The resulting residue was diluted with ethyl acetate and extracted with aqueous NaOH solution (1N) and the aqueous layer acidified with aqueous HCl solution (12N) until a precipitate formed. The precipitate was collected and used in the next step without further purification (520 mg, 85% yield).

20

Step B: Ethyl 2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio) acetate

[00277] A mixture of 1-(Naphthalen-1-yl)-1*H*-tetrazole-5-thiol (235mg, 1.03 mmol), ethyl bromoacetate (189mg, 1.13 mmol) and potassium carbonate (171mg, 1.24 mmol) in DMF (3mL) was stirred at room temperature for 16 hours. Water was then added to the reaction mixture and the precipitate that formed collected to give ethyl 2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio) acetate as a solid (306 mg, 94%).


25

Step C: 2-(1-(Naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)acetic acid

[00278] A mixture of ethyl 2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio) acetate (269mg, 0.86 mmol), aqueous sodium hydroxide solution (10%, 5mL) and methanol (10mL) was stirred at reflux for 2 hours. The reaction was then cooled to room temperature and the methanol removed. Water was added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) afforded compound 2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)acetic acid as a solid.

[00279] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.1 (s, 1H), 8.4 (d, *J*=8.1 Hz, 1H), 8.2 (d, *J*=8.1 Hz, 1H), 7.9 (m, 4H), 7.5 (d, *J*=8.3 Hz, 1H), 4.3 (s, 2H).


Example 6-2: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)propanoic acid



[00280] 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)propanoic acid was prepared according to the same procedures described in example 6-1, using 2-bromo-2-methylpropanoic acid in place of 2-bromoacetic acid.

[00281] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.1 (s, 1H), 8.4 (d, *J*=8.04 Hz, 1H), 8.2 (d, *J*=8.04 Hz, 1H), 7.9 (m, 4H), 7.1 (d, *J*=8.3 Hz, 1H), 1.7 (s, 6H).

Example 6-3: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)propanoic acid



Step A: 1-(Naphthalen-1-yl)-1*H*-tetrazol-5-ol

[00282] To a mixture of sodium hydroxide (114mg, 2.9 mmol) in water (0.5mL) was added 1-(naphthalen-1-yl)-1*H*-tetrazole-5-thiol (490mg, 2.2 mmol) and ethanol (5mL). The reaction mixture was then cooled to 0°C, propylene oxide (168mg, 2.9 mmol) added dropwise and the mixture stirred at 0°C for 30 minutes and then room temperature for 5 hours. The mixture was taken up and washed with ethyl acetate. The aqueous layer was acidified with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to give pure 1-(naphthalen-1-yl)-1*H*-tetrazol-5-ol (420mg, 90%).

Step B: Ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-yloxy) propanoate

[00283] A mixture of 1-(naphthalen-1-yl)-1*H*-tetrazol-5-ol (200mg, 0.54 mmol), ethyl bromoisobutyrate (0.16mL, 1.04 mmol) and potassium carbonate (160mg, 1.12 mmol) in DMF (3mL) was stirred at room temperature for 16 hours. Water was added and the mixture extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by preparative thin layer

chromatography (95% dichloromethane/5% methanol) afforded ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-yloxy) propanoate.

Step C: 2-Methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-ylthio)propanoic acid

[00284] A mixture of ethyl 2-methyl-2-(1-(naphthalen-1-yl)-1*H*-tetrazol-5-yloxy) propanoate (39mg,

0.12 mmol), aqueous sodium hydroxide solution (10%, 5mL) and methanol (5mL) was stirred at reflux for 2 hours. The reaction was then cooled to room temperature and the methanol removed.


Water was added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane /5% methanol) afforded 2-methyl-2-(1-(naphthalen-1-yl)-

1*H*-tetrazol-5-ylthio)propanoic acid as a solid (19mg, 55%).

[00285] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.0 (s, 1H), 8.24 (d, J=7.8 Hz, 1H), 8.14(d, J=8.1 Hz, 1H), 7.8 (m, 5H), 7.1 (d, J=8.3 Hz, 1H), 1.89 (s, 6H).


Example 7: Compounds of Formula (VII-A), (VII-B), (VII-C) and (VII-D)

[00286] Compounds of Formula (VII-A), (VII-B), (VII-C) and (VII-D) are compounds of Formula (I), wherein Ar is an oxazole, a thiazole, an isoxazole or an isothiazole




Example 7C:

[00287] Compounds of Formula (VII-C), , can be prepared according to the general scheme below:



Example 7C-1: 2-(3-Methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetate



Step A: Ethyl 2-(naphthalen-1-yl)-3-oxobutanoate

[00288] Ethyl acetate (1eq) and sodium metal (0.5eq) are added to ethyl 2-(naphthalen-1-yl)acetate (1eq) and the mixture heated at reflux with stirring, until full dissolution of the sodium metal. Upon dissolution, dry diethyl ether is added and the solution is refluxed overnight. After cooling, the solvent is removed under reduced pressure and the resulting residue acidified with sulfuric acid (15%, 50mL). The solution is extracted with ether and the ether layer dried (anhydrous sodium sulfate) and concentrated to give ethyl 2-(naphthalen-1-yl)-3-oxobutanoate.

Step B: 3-Methyl-4-(naphthalen-1-yl)isoxazol-5-ol

[00289] Ethyl 2-(naphthalen-1-yl)-3-oxobutanoate is added to methanol and hydroxylamine hydrochloride (97 %) and the mixture refluxed, with stirring, for 68 hours and then cooled. Water is added, the solution extracted with diethyl ether, and the ether layer extracted with aqueous sodium bicarbonate solution (8%). The aqueous layer is acidified to pH2 with aqueous HCl solution (36%), extracted with ether, the ether layer dried (anhydrous sodium sulfate) and concentrated to give 3-methyl-4-(naphthalen-1-yl)isoxazol-5-ol.


Step C: Ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetate

[00290] A mixture of 3-methyl-4-(naphthalen-1-yl)isoxazol-5-ol (1eq), ethyl 2-bromoacetate (2eq) and potassium carbonate (2eq) in DMF is stirred at room temperature for 16 hours. Water is added and the mixture extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) provides ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetate.

Step D: 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetic acid

[00291] A mixture of ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetate, aqueous sodium hydroxide solution (10%) and methanol is stirred at reflux for 2 hours, cooled and the methanol removed. Water is added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer is dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane /5% methanol) provides 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-yloxy)acetic acid.

Example 7C-2: 2-(3-Methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetic acid



Steps A & B: 3-Methyl-4-(naphthalen-1-yl)isoxazol-5-ol

[00292] Steps A and B are performed as described herein for example 7C-1, to provide 3-methyl-4-(naphthalen-1-yl)isoxazol-5-ol.

Step C: 3-Methyl-4-(naphthalen-1-yl)isoxazole-5-thiol

[00293] A mixture of 3-methyl-4-(naphthalen-1-yl)isoxazol-5-ol and Lawesson's reagent in toluene are heated under reflux for 4 h. The reaction mixture is concentrated under reduced pressure and the residue purified by flash chromatography (dichloromethane acetone, 95:5) to afford 3-methyl-4-(naphthalen-1-yl)isoxazole-5-thiol.

Step D: Ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetate


[00294] A mixture of 3-methyl-4-(naphthalen-1-yl)isoxazol-5-thiol (1eq), ethyl 2-bromoacetate (2eq) and potassium carbonate (2eq) in DMF is stirred at room temperature for 16 hours. Water is added and the mixture extracted with ethyl acetate, dried over sodium sulfate and concentrated.

Purification by preparative thin layer chromatography (95% dichloromethane/5% methanol) provides ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetate.


Step E: 2-(3-Methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetic acid

[00295] A mixture of ethyl 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetate, aqueous sodium hydroxide solution (10%) and methanol is stirred at reflux for 2 hours, cooled and the methanol removed. Water is added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer is dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% dichloromethane /5% methanol) provides 2-(3-methyl-4-(naphthalen-1-yl)isoxazol-5-ylthio)acetic acid.


Example 7D:



[00296] Compounds of Formula (VII-D), can be prepared according to the general scheme below:



Example 7D-1: 2-(3-Methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetic acid



Step A: 2-(Naphthalen-1-yl)-3-oxobutanal

[00297] Ethyl formate (1eq) and sodium metal (0.5eq) are added to ethyl 2-(naphthalen-1-yl)acetate (1eq) and the mixture heated at reflux with stirring, until full dissolution of the sodium metal. Upon dissolution, dry diethyl ether is added and the solution is refluxed overnight. After cooling, the solvent is removed under reduced pressure and the resulting residue acidified with sulfuric acid (15%, 50mL). The solution is extracted with ether and the ether layer dried (anhydrous sodium sulfate) and concentrated to give 2-(naphthalen-1-yl)-3-oxobutanal.

Step B: 3-Methyl-4-(naphthalen-1-yl)isoxazole

[00298] 2-(Naphthalen-1-yl)-3-oxobutanal is added to methanol and hydroxylamine hydrochloride (97%) and the mixture refluxed, with stirring, for 68 hours and then cooled. Water is added, the solution extracted with diethyl ether, and the ether layer extracted with aqueous sodium bicarbonate solution (8%). The aqueous layer is acidified to pH2 with aqueous HCl solution (36%), extracted with ether, the ether layer dried (anhydrous sodium sulfate) and concentrated to give 3-methyl-4-(naphthalen-1-yl)isoxazole.

Step C: 3-Methyl-4-(naphthalen-1-yl)isothiazole

[00299] 3-methyl-4-(naphthalen-1-yl)isoxazole is reduced by treatment with Raney nickel and the resulting enamino ketone is treated with phosphorus pentasulfide and chloranil to provide 3-methyl-4-(naphthalen-1-yl)isothiazole (see McGregor *et al*, *Tetrahedron*, **1969**, 25 (2), 389-395).

Step D: Ethyl 2-(3-methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetate

[00300] 3-Methyl-4-(naphthalen-1-yl)isothiazole is brominated by treatment with PBr₃ (0.1eq) and NBS (1eq) in THF at -78°C for 1h and then room temperature for 3 hrs. Treatment with ⁿBuLi (1eq) and TMEDA (1eq) in THF at -78°C for 1 hr, achieves lithium-halogen exchange, and the lithide is then treated with TIPS-S-S-TIPS (1eq) at -78°C to room temperature over 2 hr, to provide the thio derivative. Removal of the protecting group in the presence of ethyl bromoacetate, by adding ethyl bromoacetate (2.5eq) in toluene/DMF (1/1) at 0°C, and then adding TBAF (2.5eq in toluene) and reacting for 30mins affords ethyl 2-(3-methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetate.


Step E: 2-(3-Methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetic acid

[00301] A mixture of ethyl 2-(3-methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetate, aqueous sodium hydroxide solution (10%) and methanol is stirred at reflux for 2 hours, cooled and the methanol removed. Water is added, neutralized with aqueous HCl solution (1N) and extracted with ethyl acetate. The organic layer is dried over sodium sulfate and concentrated. Purification by


preparative thin layer chromatography (95% dichloromethane /5% methanol) provides 2-(3-methyl-4-(naphthalen-1-yl)isothiazol-5-ylthio)acetic acid.

Example 8: Compounds of Formula (VIII-A) – (VIII-L)


- 5 **[00302]** Compounds of Formula (VIII-A) – (VIII-L) are compounds of Formula (I), wherein R^1 is H and Ar is an oxazole, a thiazole, an isoxazole or an isothiazole




(VIII-A)




(VIII-B)




(VIII-C)




(VIII -D)




(VIII-E)




(VIII-F)




(VIII-G)




(VIII-H)




(VIII-I)



(VIII-J)





(VIII-K)




(VIII-L)


Example 8A:

- 15 **[00303]** Compounds of Formula (VIII-A), , can be prepared according to the general scheme below:




Example 8B:

- 20 **[00304]** Compounds of Formula (VIII-B), , can be prepared according to the general scheme below:



Example 8B-1: 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetic acid

[00305] 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetic acid is prepared according as outlined below.



5 Step A: 2-Bromo-1-(2-chloro-4-methylphenyl)ethanone

[00306] A solution of bromine (1.16mL, 22.4 mmol) in 1,4-dioxane (50mL) is added to a solution of 1-(2-chloro-4-methylphenyl) ethanone 2 (3.45 g, 20.4 mmol) in 1,4-dioxane (20mL) at room temperature over a period of 1 h, and the reaction mixture stirred at room temperature for 20 min. The 1,4-dioxane is removed under reduced pressure and the residue dissolved in ether (100mL). The resulting solution is successively washed with aqueous saturated NaHCO₃, water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane:hexane, 7:3) to yield 2-bromo-1-(2-chloro-4-methylphenyl)ethanone.

Step B: Methyl 2-(2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate

15 [00307] Methyl thioglycolate (379μL, 4.24 mmol) is added to a solution of 2-bromo-1-(2-chloro-4-methylphenyl)ethanone (1.00 g, 4.04 mmol) and Et₃N (619μL, 4.44 mmol) in dichloromethane, and stirred at room temperature for 1 h. The mixture is diluted with dichloromethane (100mL), and washed successively with aqueous HCl solution (0.1N), aqueous saturated NaHCO₃, water and brine. The organic layer is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane:acetone, 95:5) to afford methyl 2-(2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate.

Step C: Methyl 2-(1-bromo-2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate

25 [00308] A solution of bromine (202μL, 3.93 mmol) in acetic acid (10mL) is added over 30 min, to a solution of methyl 2-(2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate (1.07 g, 3.93 mmol) in acetic acid (30mL), at room temperature and stirred at room temperature for 30 min. The reaction mixture is poured into ether (200mL), and the organic phase successively washed with water, aqueous saturated NaHCO₃, water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by flash chromatography (dichloromethane) to afford methyl 2-(1-bromo-2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate.

Step D: Methyl 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetate

[00309] Thioformamide (521.3 mg, 8.53 mmol) is added to a solution of methyl 2-(1-bromo-2-(2-chloro-4-methylphenyl)-2-oxoethylthio)acetate (300.0 mg, 853.1 μmol) in isopropanol (20mL), stirred at 60°C for 1 h and then concentrated under reduced pressure. The residue is purified by flash


chromatography (dichloromethane:acetone, 95:5) to afford methyl 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetate.

Step E: 2-(4-(2-Chloro-4-methylphenyl)thiazol-5-ylthio)acetic acid


[00310] Aqueous sodium hydroxide solution (1N, 2.0mL, 2.0 mmol) is added to a solution of methyl 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetate (207 mg, 660.9 μ mol) in DMSO (6.0mL), and the mixture stirred at room temperature for 1 h. The mixture is then acidified by addition of TFA (pH = 2), diluted with ethyl acetate (100mL), successively washed with water and brine, dried over magnesium sulfate, filtered and concentrated under vacuum to give 2-(4-(2-chloro-4-methylphenyl)thiazol-5-ylthio)acetic acid.


Example 9: Compounds of Formula (IX-A), (IX-B), (IX-C), (IX-D), (IX-E) and (IX-F)

[00311] Compounds of Formula (IX-A), (IX-B), (IX-C), (IX-D), (IX-E) and (IX-F) are compounds of Formula (I), wherein R^1 is H and Ar is an oxadiazole or a thiadiazole




Example 9B:

[00312] Compounds of Formula (IX-B),  can be prepared according to the general scheme below:



Example 9B-1: 2-(4-(Naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetic acid



Step A: 2-bromo-1-(naphthalen-1-yl)ethanone

[00313] To a solution of 1-(naphthalen-1-yl)ethanone (500 mg, 2.9 mmol) in dioxane (5 mL) was added to a solution of bromine (510 mg, 3.19 mmol) in dioxane (10 mL), at room temperature, over a period of 30 minutes. The reaction mixture was then stirred at room temperature for 20 minutes and concentrated. The resulting residue was diluted with ether and washed with saturated sodium bicarbonate, water, dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (70% DCM/30% hexanes) afforded 2-bromo-1-(naphthalen-1-yl)ethanone (673 mg, 93%).

Step B: 2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethanone

[00314] A mixture of 2-bromo-1-(naphthalen-1-yl)ethanone (1g, 4.02 mmol), benzotriazole (530mg, 4.42 mmol) and K₂CO₃ (560 mg, 4.02 mmol) in toluene (100 mL) was heated at reflux for 16 hours. The reaction was cooled to room temperature, washed with water, dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (100% DCM) afforded 2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethanone as a tan solid.

Step C: (Z)-N'-(2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethylidene)-4-methylbenzene sulfonylhydrazide

[00315] A solution of 2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethanone (770mg, 2.68 mmol) and *p*-toluenesulfonyl hydrazide (500 mg, 2.68 mmol) in toluene (25 mL) was stirred at reflux for 2 days. The reaction mixture was cooled to room temperature and concentrated to give (Z)-N'-(2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethylidene)-4-methylbenzenesulfonylhydrazide as a tan solid that was used in the next step without further purification.

Step D: 5-(1*H*-benzo[d][1,2,3]triazol-1-yl)-4-(naphthalen-1-yl)-1,2,3-thiadiazole

[00316] A mixture of (Z)-N'-(2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1-(naphthalen-1-yl)ethylidene)-4-methylbenzenesulfonylhydrazide (1g, 2.19 mmol) and SOCl₂ (25 mL) was stirred at 60 °C for 18 h and then concentrated and purified by TLC (100% DCM) to afford 5-(1*H*-benzo[d][1,2,3]triazol-1-yl)-4-(naphthalen-1-yl)-1,2,3-thiadiazole as an amber solid.

Step E: Methyl 2-(4-(naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetate

[00317] NaOH (60% oil, 30 mg, 0.61 mmol) was added to a solution of 5-(1*H*-benzo[d][1,2,3]triazol-1-yl)-4-(naphthalen-1-yl)-1,2,3-thiadiazole and methylthioglycolate (64mg, 0.61 mmol) in DMF (3 mL) and the mixture was stirred at room temperature for 2 h. 1N HCl was then added and the mixture was extracted with ethyl acetate, dried over Na₂SO₄ and concentrated. Purification by TLC (100% DCM) afforded methyl 2-(4-(naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetate.

Step F: 2-(4-(Naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetic acid

[00318] A mixture of methyl 2-(4-(naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetate (60mg, 0.19 mmol), sodium hydroxide (10% aq. 5 mL) and methanol (5 mL) was stirred at reflux for 2 hours.

The reaction was then cooled to room and the methanol removed. Water was added, neutralized with 1N HCl and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Purification by preparative thin layer chromatography (95% DCM/5% MeOH) afforded 2-(4-(Naphthalen-1-yl)-1,2,3-thiadiazol-5-ylthio)acetic acid as a solid.

5 [00319] ¹H NMR (DMSO-*d*₆, 400MHz): δ 13.3 (s, 1H), 8.19 (d, J=8.2 Hz, 1H), 8.13 (d, J=8.2 Hz, 1H), 7.70 (m, 4H), 4.12 (s, 2H).

II In vitro testing

Example 10: Uric Acid Uptake Assay (URAT-1 EC₅₀)

10 [00320] Creation of Stable Cell Lines Expressing hURAT1 Transporter: Full-length human URAT1 gene (SLC22A12) was subcloned from plasmid pCMV6-XL5 (Origene) into eukaryotic expression plasmid pCMV6/Neo (Origene) using Not I restriction sites. Gene sequencing confirmed the sequence of hURAT1 as outlined in Genbank (Accession #NM_144585.2). HEK293 human embryonic kidney cells (ATCC# CRL-1573) were propagated in EMEM tissue culture medium as
15 described by ATCC in an atmosphere of 5% CO₂ and 95% air. Transfections of HEK293 cells with the pCMV6/Neo/URAT1 construct were performed using L2000 transfection reagent (Invitrogen) as described by the manufacturer. After 24h the transfected cells were split into 10 cm tissue culture plates and grown for 1 day after which the medium was replaced with fresh growth medium containing G418 (Gibco) at 0.5 mg/ml final concentration. Drug-resistant colonies were selected
20 after approximately 8 days and then tested for ¹⁴C-uric acid transport activity. The HEK293/urat1 cells are plated on Poly-D-Lysine Coated 96-well Plates at a density of 75,000 cells per well. Cells were grown overnight (20-26 hours) at 37°C in an incubator. Plates were allowed to come to room temperature and media was washed out with one wash of 250 µl of Wash Buffer (125mM Na Gluconate, 10 mM Hepes ph 7.3). Compound or vehicle is added in assay buffer with C14 Uric Acid
25 for a final concentration of 40µM Uric Acid with a specific activity of 54 mCi/mmol. Assay Buffer is 125mM Sodium Gluconate, 4.8mM Potassium Gluconate, 1.2 mM Potassium phosphate, monobasic, 1.2mM magnesium sulfate, 1.3mM Ca Gluconate, 5.6mM Glucose, 25mM HEPES, pH 7.3. Plates were incubated at room temperature for 10 minutes then washed 3 times with 50µl Wash Buffer and 3 times with 250µl Wash Buffer. Microscint 20 Scintillation Fluid was added and plates
30 were incubated overnight at 45°C to equilibrate. Plates are then read on the TopCount Plate Reader and an EC50 value generated. (See Enomoto *et al*, *Nature*, **2002**, 417, 447-451 and Anzai *et al*, *J. Biol. Chem.*, **2004**, 279, 45942-45950.)

Compounds of Formula (I), prepared as described above in examples 1-11, were examined according to the procedure described above and EC₅₀ values generated. The table below summarizes
35 the activity of the compounds in the Uric Acid Uptake Assay, wherein A represents an EC₅₀ from 1

nM to 1 μ M; B represents an EC₅₀ from 1 μ M to 30 μ M; and C represents an EC₅₀ greater than 30 μ M. (N/A means data not available).










Example 11: URAT-1 Activity of select compounds (Uric Acid Uptake Assay)



5 **[00321]** Compounds prepared as described above, were examined according to the procedure described herein and EC₅₀ values generated. The table below summarizes the activity of the compounds in the Uric Acid Uptake Assay, wherein

A represents an EC₅₀ <5 μ M;

B represents an EC₅₀ from 5 μ M to 20 μ M; and

10 C represents an EC₅₀ >20 μ M.


Eg	Structure	EC ₅₀ (μ M) (URAT-1)
4D-1		B
4D-2		A
4E-1 (step C)		A
4E-1(step D)		A
5A-1		C
5A-2		A
6-1 (step C)		B
6-1 (step D)		C
6-2		A

6-3		C
9B-1		B

CLAIMS

WHAT IS CLAIMED IS:


- 5 1. A compound of Formula (I):



wherein

- 10 R^1 is an electron lone pair, H, Br, Cl, Br, I, NH_2 , methyl, ethyl, *n*-propyl, *i*-propyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted *n*-propyl, optionally substituted *i*-propyl, CF_3 , CHF_2 or CH_2F ;

R^2 is



wherein

- 15 each R^{4a} and R^{4b} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$; or

- 20 R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N;

each R^{4c} and R^{4d} is independently selected from H, F, Cl, Br, CH_3 , CF_3 , CFH_2 , CF_2H , ethyl, *i*-propyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, OH, OCF_3 , NH_2 , $NHCH_3$;

- 25 R^P is H, methyl, ethyl, propyl, *i*-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or CN;

R^3 is $-X-CR^{5a}R^{5b}-(CR^{6a}R^{6b})_n-C(O)-O-R^M$

wherein

X is S or O;

each R^{5a} , R^{5b} , R^{6a} and R^{6b} is independently selected from H, F, Cl, Br, CH_3 and CF_3 ;

n is 0 or 1; and

R^M is H, a pharmaceutically acceptable cation, substituted or unsubstituted (C_{1-6})alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a prodrug moiety;

Ar is a 5-membered aromatic heterocycle comprising from one to four heteroatoms each independently selected from O, N and S;

and wherein the groups R^1 , R^2 and R^3 are immediately adjacent to each other.

2. A compound of claim 1, wherein Ar is a pyrrole, a pyrazole, an imidazole, a triazole, a tetrazole, an oxazole, a thiazole, an isoxazole, an isothiazole, an oxadiazole or a thiadiazole.


3. A compound of claim 2, wherein

Ar is a pyrrole of Formula (II-A), (II-B), (II-C) or (II-D); or


Ar is a pyrazole or an imidazole of Formula (IV-A), (IV-B), (IV-C), (IV-D) or (IV-E); or

Ar is a triazole of Formula (V-A) or (V-B); or


Ar is a tetrazole of Formula (VI):




(II-A)




(II-B)




(II-C)




(II-D)




(IV-A)




(IV-B)




(IV-C)




(IV-D)




(IV-E)



(V-A)



(V-B)



(VI)


or a tautomer thereof.

4. A compound of claim 2, wherein


Ar is an oxazole, a thiazole, an isoxazole or an isothiazole of Formula (VII-A), (VII-B), (VII-C) or (VII-D); or

R^1 is H and Ar is an oxazole, a thiazole, an isoxazole or an isothiazole of Formula (VIII-A), (VIII-B), (VIII-C), (VIII-D), (VIII-E), (VIII-F), (VIII-G), (VIII-H), (VIII-I), (VIII-J), (VIII-K) or (VIII-L); or


R^1 is H and Ar is an oxadiazole or a thiadiazole of Formula (IX-A), (IX-B), (IX-C), (IX-D), (IX-E) or (IX-F).




(VII-A)




(VII-B)




(VII-C)




(VII-D)




(VIII-A)




(VIII-B)




(VIII-C)




(VIII-D)




(VIII-E)




(VIII-F)




(VIII-G)




(VIII-H)




(VIII-I)




(VIII-J)




(VIII-K)




(VIII-L)




(IX-A)




(IX-B)




(IX-C)



(IX-D)




(IX-E)



(IX-F)

or a tautomer thereof.


5. The compound of claim 2, wherein R^2 is



20

6. The compound of claim 2, wherein R^{4a} and R^{4b} , together with the carbon atoms to which they are attached, form a 5- or 6-membered saturated, unsaturated or aromatic ring which optionally contains from one to three heteroatoms each independently selected from O, S and N.

7. The compound of claim 2, wherein R^2 is



5 8. The compound of claim 2, wherein R^P is cyclopropyl or CN.

9. The compound of claim 2, wherein X is O.

10. The compound of claim 2, wherein n is 0.

10

11. The compound of claim 2, wherein R^{5a} is H and R^{5b} is H.

12. The compound of claim 2, wherein n is 0, R^{5a} is H and R^{5b} is H.

15 13. The compound of claim 2, wherein n is 0, R^{5a} is F and R^{5b} is F.

14. The compound of claim 2, wherein R^M is H.

15. The compound of claim 2, wherein R^M is a pharmaceutically acceptable cation.

20

16. A method for decreasing uric acid levels in one or more tissues or organs of a subject, comprising administering to the subject a uric acid level decreasing amount of a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.

25

17. The method of claim 16, wherein the subject has a disorder characterized by an abnormally high content of uric acid in one or more tissues or organs.

18. The method of claim 17, wherein the disorder is characterized by overproduction of uric acid, low excretion of uric acid, tumor lysis, a blood disorder or a combination thereof.

30

19. The method of claim **16**, wherein the tissue or organ is blood, serum or plasma.
20. The method of claim **16**, wherein said uric acid levels are decreased by at least about 10% to at least about 50% in one or more tissues or organs of the subject.
- 5 21. The method of claim **16**, wherein the reduction in uric acid levels results in a reduction in hypertension or cardiovascular events.
22. A method for
- 10 a) reducing uric acid production, increasing uric acid excretion or both in a subject; or
b) treating or preventing hyperuricemia in a subject; or
c) treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid; or
d) preventing a condition characterized by abnormal tissue levels of uric acid in a subject at
15 increased risk of developing the condition; or
e) treating hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency; or
f) preventing the formation or reducing the size of tophi/tophus in a subject;
- comprising administering to the subject a compound of Formula (I) or a metabolite,
pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- 20 23. The method of any of the preceding claims, wherein the method is for treating a condition selected from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis,
25 urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis.
24. The method of claim **23**, wherein the condition is gout.
25. The method of claim **23**, wherein the condition is joint inflammation.
- 30 26. The method claim **23**, further comprising administering an agent effective for the treatment of the condition.
27. The method of claim **26**, wherein the agent is effective in reducing tissue levels of uric acid.
- 35

28. The method of claim **26**, wherein the agent is a nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, a corticosteroid, adrenocorticotrophic hormone (ACTH), probenecid, sulfinpyrazone febuxostat or allopurinol.

5 29. The method of claim **26**, wherein the agent is allopurinol

30. The method of claim **26**, wherein the agent is febuxostat

31. A pharmaceutical composition comprising:

- 10 i) a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof;
ii) allopurinol; and
iii) optionally one or more pharmaceutically acceptable carriers.

15 32. A pharmaceutical composition comprising:

- i) a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof;
ii) febuxostat; and
iii) optionally one or more pharmaceutically acceptable carriers.

20

33. A pharmaceutical composition comprising:

- i) a compound of Formula (I) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof;
ii) at least one agent selected from the group consisting of a nonsteroidal anti-inflammatory drug
25 (NSAID), Ibuprofen, Naproxen, Colchicine, Probenecid, an antihypertensive agent, an anticancer agent, and Sulfinpyrazone; and
iii) optionally one or more pharmaceutically acceptable carriers.